<SEC-DOCUMENT>0001193125-22-046719.txt : 20220218
<SEC-HEADER>0001193125-22-046719.hdr.sgml : 20220218
<ACCEPTANCE-DATETIME>20220218170936
ACCESSION NUMBER:		0001193125-22-046719
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20220216
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220218
DATE AS OF CHANGE:		20220218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lyra Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001327273
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39273
		FILM NUMBER:		22653796

	BUSINESS ADDRESS:	
		STREET 1:		480 ARSENAL STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-373-4600

	MAIL ADDRESS:	
		STREET 1:		480 ARSENAL STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	480 Biomedical, Inc.
		DATE OF NAME CHANGE:	20120927

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsenal Vascular, Inc.
		DATE OF NAME CHANGE:	20110826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsenal Medical, Inc.
		DATE OF NAME CHANGE:	20090414
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d309078d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lyra="http://lyratherapeutics.com/20220216" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-02-16_to_2022-02-16">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-02-16_to_2022-02-16">0001327273</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="lyra-20220216.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-02-16_to_2022-02-16"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001327273</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-16</xbrli:startDate> <xbrli:endDate>2022-02-16</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-02-16_to_2022-02-16">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-02-16_to_2022-02-16" format="ixt:datemonthdayyearen">February&#160;16, 2022</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-02-16_to_2022-02-16">LYRA THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-02-16_to_2022-02-16" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-02-16_to_2022-02-16">001-39273</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-02-16_to_2022-02-16">84-1700838</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-02-16_to_2022-02-16">480 Arsenal Way</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-02-16_to_2022-02-16">Watertown</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-02-16_to_2022-02-16">MA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-02-16_to_2022-02-16">02472</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices) (Zip Code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-02-16_to_2022-02-16">(617)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-02-16_to_2022-02-16">393-4600</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, include area code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-02-16_to_2022-02-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-02-16_to_2022-02-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-02-16_to_2022-02-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-02-16_to_2022-02-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-02-16_to_2022-02-16">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-02-16_to_2022-02-16">LYRA</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-02-16_to_2022-02-16" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#160;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-02-16_to_2022-02-16" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2022-02-16_to_2022-02-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;5.02.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;16, 2022, the Board of Directors of Lyra Therapeutics, Inc. (the &#8220;Company&#8221;) appointed Harlan Waksal, M.D. as a Class&#160;II director of the Company and Chairperson of the Board, and as the Executive Chair and an executive officer of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into an employment agreement with Dr.&#160;Waksal for an unspecified term (the &#8220;Waksal Employment Agreement&#8221;). Under the terms of the Waksal Employment Agreement, Dr.&#160;Waksal will receive an annual base salary of $200,000. In the event the Company consummates a change in control where the &#8220;market capitalization&#8221; (as such term is defined in the Waksal Employment Agreement) of the Company equals or exceeds minimum value of $750&#160;million<span style="text-decoration:underline">,</span>&#160;Dr.&#160;Waksal shall be entitled to a cash bonus in the amount of 1% of such market capitalization&#160;(&#8220;Waksal Transaction Bonus&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company terminates the&#160;employment&#160;of Dr.&#160;Waksal without &#8220;cause&#8221; or Dr.&#160;Waksal resigns for &#8220;good reason&#8221; (as each such terms are defined in the Waksal Employment Agreement), subject to Dr.&#160;Waksal&#8217;s timely&#160;execution of a release of claims and continued compliance with a separate restrictive covenant agreement (described below), Dr.&#160;Waksal is entitled to receive (i)&#160;base salary continuation for a period of 12 months; (ii)&#160;direct payment of or reimbursement for continued medical, dental and vision coverage pursuant to COBRA for up to 12 months, less the amount he would have had to pay to receive such coverage as an active employee based on the cost sharing levels in effect on Dr.&#160;Waksal&#8217;s termination date; and (iii)&#160;any options issued to Dr.&#160;Waksal under the Inducement Award Plan or other equity plans maintained by the Company may, to the extent vested and exercisable as of the date of Dr.&#160;Waksal&#8217;s termination of employment, be exercised until the earlier of twelve months from the date of termination or the expiration date set forth in the applicable option award agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company terminates Dr.&#160;Waksal without &#8220;cause&#8221; or Dr.&#160;Waksal resigns for &#8220;good reason,&#8221; in either case, on or within three months prior to or 12&#160;months following a &#8220;change in control&#8221; (as defined in the Waksal Employment Agreement), then, in lieu of the severance benefits described above, subject to Dr.&#160;Waksal&#8217;s timely execution of a release of claims, Dr.&#160;Waksal is entitled to receive (i)&#160;base salary continuation for a period of 18 months; (ii)&#160;direct payment of or reimbursement for continued medical, dental and vision coverage pursuant to COBRA for up to 18 months, less the amount he would have had to pay to receive such coverage as an active employee based on the cost sharing levels in effect on Dr.&#160;Waksal&#8217;s termination date; (iii)&#160;accelerated vesting of all unvested equity or equity-based awards that vest solely based on the passage of time, with any such awards that vest based on the attainment of performance-vesting conditions being governed by the terms of the applicable award agreement; and (iv)&#160;the Waksal Transaction Bonus to the extent the conditions for issuance under the Waksal Employment Agreement are otherwise satisfied. Dr.&#160;Waksal has agreed to refrain from competing with us while employed and following his termination of employment for any reason other than by the Company without &#8220;cause&#8221; for a period of one year and to refrain from soliciting our employees or customers while employed and following his termination of employment for any reason for a period of one year. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;16, 2022, the Board approved the adoption of the Lyra Therapeutics, Inc. 2022 Employment Inducement Award Plan (the &#8220;Inducement Award Plan&#8221;), which was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules (&#8220;Rule 5635(c)(4)&#8221;). In accordance with Rule 5635(c)(4), awards made under the Inducement Award Plan may only be made to a newly hired employee who has not previously been a member of the Board, or any employee who is being rehired following a bona fide period of <span style="white-space:nowrap">non-employment</span> by the Company or a subsidiary, as a material inducement to the employee&#8217;s entering into employment with the Company or its subsidiary. An aggregate of 520,000 shares of the Company&#8217;s common stock have been reserved for issuance under the Inducement Award Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with his appointment as an executive officer, Dr.&#160;Waksal was granted an option to purchase 520,000 shares of the Company&#8217;s common stock under the Inducement Award Plan (the &#8220;Initial Option&#8221;). The Initial Option issued to Dr.&#160;Waksal has an exercise price per share of $4.21, which was the closing price per share of the Company&#8217;s common stock on the date of grant of the option. The Initial Option vests as to <span style="white-space:nowrap">one-third</span> of the shares underlying the option, in each case, upon the achievement of three distinct market capitalization targets during the five-year performance period following the date of grant, provided that, except as provided below, no more than <span style="white-space:nowrap">one-third</span> of the option may vest prior to the first anniversary of the date of grant, no more than <span style="white-space:nowrap">two-thirds</span> of the option may vest prior to the second anniversary of the date of grant and the option may not become fully vested </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">prior to the third anniversary of the date of grant, subject to Dr.&#160;Waksal&#8217;s continued service on each applicable vesting date. The option&#8217;s final expiration date is February&#160;15, 2032. The market capitalization of the Company will be periodically assessed to determine achievement of the market capitalization targets, based on the Company&#8217;s <span style="white-space:nowrap">30-trading</span> day VWAP and the average number of outstanding shares in such period; provided, however, in the event of a &#8220;change in control&#8221; (as defined in the Inducement Award Plan) prior to the end of the performance period, the achievement of the market capitalization targets shall be deemed satisfied upon the effective time of such change in control. If the change in control occurs prior to the satisfaction of any time-based vesting conditions, to the extent the Initial Option is assumed, substituted, or continued in such change in control it shall continue to be eligible to vest upon the satisfaction of the time-based vesting conditions and to the extent the Initial Option is not assumed, substituted or continued in such change in control, the Initial Option will become vested as of immediately prior to the change in control, provided, that, in the event that Dr.&#160;Waksal&#8217;s service is terminated by the Company without &#8220;cause&#8221; or due to his resignation with &#8220;good reason,&#8221; (as such terms are defined in the Waksal Employment Agreement), in either case within 3 months preceding or 12 months following the date of a change in control, such options shall vest immediately as of the later of the termination date and the change in control, subject to Dr.&#160;Waksal&#8217;s execution of a release of claims against the Company. The Waksal Employment Agreement also provides for the Company to grant Dr.&#160;Waksal an anti-dilutive option in an amount equal to the difference between the shares subject to the Initial Option and four percent of the &#8220;capitalization&#8221; (as defined in the Waksal Employment Agreement) of the Company immediately following the first bona fide equity financing of the Company following the date of the Waksal Employment Agreement. Such anti-dilutive grant, if granted, will be subject to the same vesting terms as the Initial Option. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;16, 2022, the Company entered into an amendment to its employment agreement with its President and Chief Executive Officer, Maria Palasis, Ph.D. (the &#8220;Amendment&#8221;). Pursuant to the Amendment, if the Company terminates the&#160;employment&#160;of Dr.&#160;Palasis without &#8220;cause&#8221; or Dr.&#160;Palasis resigns for &#8220;good reason&#8221; (as each such terms are defined in the employment agreement with Dr.&#160;Palasis), any options issued to Dr.&#160;Palasis under the equity plans maintained by the Company may, to the extent vested as of the date of Dr.&#160;Palasis&#8217; termination of employment, be exercised until the earlier of 15 months from such date or the expiration date set forth in the applicable option award agreement. The Amendment further provides that, in the event the Company consummates a change in control (as such term is defined in the employment agreement with Dr.&#160;Palasis) where the &#8220;market capitalization&#8221; (as such term is defined in the Amendment) of the Company equals or exceeds a minimum value of $750&#160;million<span style="text-decoration:underline">,</span>&#160;Dr.&#160;Palasis shall be entitled to a cash bonus in the amount of 1% of such market capitalization (the &#8220;Palasis Transaction Bonus&#8221;), and if the Company terminates Dr.&#160;Palasis without &#8220;cause&#8221; or Dr.&#160;Palasis resigns for &#8220;good reason,&#8221; in either case, on or within three months prior to or 12 months following a &#8220;change in control,&#8221; Dr.&#160;Palasis will be entitled to receive the Palasis Transaction Bonus upon such termination to the extent the conditions for issuance of the Palasis Transaction Bonus set forth in the Amendment are otherwise satisfied. Pursuant to the Amendment, Dr.&#160;Palasis has also agreed that the hiring of Dr.&#160;Waksal will not constitute &#8220;good reason&#8221; under the terms of her employment agreement with the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Amendment, Dr.&#160;Palasis was granted an option to purchase 175,000 shares of the Company&#8217;s common stock on February&#160;16, 2022, which option has identical terms to the Initial Option granted to Dr.&#160;Waksal. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;text-align:center">Exhibit<br />No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d309078dex101.htm">First Amendment to the Employment Agreement, dated February&#160;16, 2022, between Lyra Therapeutics, Inc. and Maria Palasis, Ph.D.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d309078dex102.htm">Employment Agreement, dated February&#160;16, 2022, between Lyra Therapeutics, Inc. and Harlan Waksal, M.D.. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d309078dex103.htm">Lyra Therapeutics, Inc. 2020 Incentive Award Plan Performance Stock Option Grant Notice and Performance Stock Option Agreement issued to Maria Palasis, Ph.D. on February&#160;16, 2022 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d309078dex104.htm">Lyra Therapeutics, Inc. 2022 Inducement Award Plan Performance Stock Option Grant Notice and Performance Stock Option Agreement issued to Harlan Waksal, M.D. on February&#160;16, 2022</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d309078dex105.htm">Lyra Therapeutics, Inc. 2022 Inducement Award Plan </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">LYRA THERAPEUTICS, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: February&#160;18, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jason Cavalier</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Jason Cavalier</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d309078dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIRST AMENDMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO THE
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT BETWEEN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. AND MARIA PALASIS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment (the &#147;<U>Amendment</U>&#148;) to that certain Employment Agreement between Lyra Therapeutics, Inc., a Delaware corporation
(together with any successor thereto, the &#147;<U>Company</U>&#148;), and Maria Palasis (the &#147;<U>Executive</U>&#148;) dated as of April&nbsp;27, 2020 (the &#147;<U>Employment Agreement</U>&#148;) is made as of this 16th day of February, 2022
(the &#147;<U>Ame</U><U>ndment Date</U>&#148;), by and among the Company and the Executive. Except as set forth in this Amendment, capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WITNESSETH </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
the Company anticipates entering into an employment agreement with Harlan Waksal (the &#147;<U>Executive Chair Agreement</U>&#148;), pursuant to which Mr.&nbsp;Waksal will serve as the Executive Chair of the Company; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, subject to the execution of the Executive Chair Agreement (the &#147;<U>Agreement Execution</U>&#148;), the Company and the Executive
desire to amend the terms of the Employment Agreement as set forth herein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Executive and the Company (collectively the &#147;<U>Parties</U>&#148;) hereby agree, subject to and effective upon the Agreement Execution, to the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Section&nbsp;2 of the Employment Agreement is hereby amended to add a new subsection (g)&nbsp;as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Transaction Bonus</U>. In connection with a Change in Control in which the Market Capitalization of the Company equals
or exceeds $750&nbsp;million, Executive shall be entitled to a cash bonus in the amount of 1.0% of the Market Capitalization (the &#147;<U>Transaction Bonus</U>&#148;). The Transaction Bonus shall be payable within thirty (30)&nbsp;days after the
completion of the Change in Control transaction, subject to Executive&#146;s continued employment with the Company through the completion of the Change in Control transaction and execution, within thirty (30)&nbsp;days after the completion of the
Change in Control transaction, of a release of claims in favor of the Company materially consistent with the terms of the release attached as <U>Exhibit B</U> to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Section&nbsp;4(b) of the Employment Agreement is hereby amended to add a new subclause (iv)&nbsp;as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) any vested and exercisable options held by Executive as of the Date of Termination, will remain outstanding and
exercisable for fifteen (15)&nbsp;months from the Date of Termination (provided that (a)&nbsp;in no event will any such option remain outstanding past the final expiration date set forth in the applicable option award agreement (b)&nbsp;all such
options will in all events remain subject to earlier termination in connection with a corporate transaction or event in accordance with the applicable option award agreement and the 2020 Incentive Award Plan, any equity plan subsequently adopted by
the Company or any successor plan, as applicable). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Section&nbsp;4(c) of the Employment Agreement is hereby amended to replace the <FONT
STYLE="white-space:nowrap">lead-in</FONT> language in its entirety as follows: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In lieu of the payments and benefits set forth in <U>Section</U><U></U><U>&nbsp;4(b)</U>, in
the event Executive&#146;s employment terminates without Cause pursuant to <U>Section</U><U></U><U>&nbsp;3(a)(iv)</U>, or due to Executive&#146;s resignation with Good Reason pursuant to <U>Section</U><U></U><U>&nbsp;3(a)(v)</U>, in either case,
within three (3)&nbsp;months prior or twelve (12)&nbsp;months following the date of a Change in Control, subject to Executive signing on or before the twenty-first (21st) day following Executive&#146;s Separation from Service or in the event that
such Separation from Service is &#147;in connection with an exit incentive or other employment termination program&#148; (as such phrase is defined in the Age Discrimination in Employment Act of 1967, as amended) on or before the forty-fifth (45th)
day following Executive&#146;s Separation from Service, and not revoking, the Release, and Executive&#146;s continued compliance with <U>Section</U><U></U><U>&nbsp;5</U>, Executive shall receive, in addition to the payments and benefits set forth in
<U>Section</U><U></U><U>&nbsp;3(c)</U>, the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. Section&nbsp;4(c) of the Employment Agreement is hereby amended to add a new
subclauses&nbsp;(v) and (vi) as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) the benefits set forth in <U>Section</U><U></U><U>&nbsp;4(b)(iv)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) The Transaction Bonus, provided that the conditions for issuance of the Transaction Bonus are otherwise satisfied in
accordance with Section&nbsp;2(g). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. Section&nbsp;7 of the Employment Agreement is hereby amended to add a new subsection (g)&nbsp;as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Market Capitalization</U>. &#147;Market Capitalization&#148; shall mean an amount equal to the product of
(i)&nbsp;the cash price per share of the Company&#146;s common stock (a &#147;<U>Share</U>&#148;) paid by an acquiror in connection with a Change in Control, or, if the consideration in the Change in Control transaction is payable in a form other
than a fixed amount of cash per Share, the closing price per Share on the last trading day preceding the closing date of the Change in Control, and (ii)&nbsp;the number of Shares outstanding as of immediately prior to the Change in Control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Waiver of Good Reason</U>. Executive expressly agrees and acknowledges that none of the Agreement Execution, the hiring of
Mr.&nbsp;Waksal as the Executive Chair, the execution of this Amendment or any matters ancillary thereto or the implementation thereof shall constitute Good Reason for purposes of the Employment Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>No Other Amendment</U>. Except as expressly set forth in this Amendment, the Employment Agreement shall remain unchanged and shall
continue in full force and effect according to its terms. In the event the Agreement Execution does not occur for any reason, this Amendment shall be null and void and of no force or effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Acknowledgement</U>. The Executive acknowledges and agrees that he has carefully read this Amendment in its entirety, fully understands
and agrees to its terms and provisions and intends and agrees that it be final and legally binding on the Executive and the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.
<U>Governing Law; Counterparts</U>. This Amendment shall be construed in accordance with the laws of the State of Delaware without reference to principles of conflicts of law and may be executed in several counterparts by the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>[Signature Page Follows] </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Executive has hereunto set the Executive&#146;s hand and the Company
has caused this Amendment to be executed in its name on its behalf, all as of the Amendment Date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LYRA THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ C. Ann Merrifield</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">C. Ann Merrifield</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Chair of the Compensation Committee of the Board of Directors</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maria Palasis, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Maria Palasis</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d309078dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Employment Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Employment Agreement (this &#147;<U>Agreement</U>&#148;), dated as of February&nbsp;16, 2022 (the &#147;<U>Effective Date</U>&#148;), is
made by and between Lyra Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the &#147;<U>Company</U>&#148;), and Harlan Waksal (&#147;<U>Executive</U>&#148;) (collectively referred to herein as the
&#147;<U>Parties</U>&#148; or individually referred to as a &#147;<U>Party</U>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is the desire of the Company to assure itself of the services of Executive as of the Effective Date and
thereafter by entering into this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive and the Company mutually desire that Executive provide services to the Company on the terms herein
provided. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and of the respective covenants and agreements set forth below, the Parties hereto agree as
follows: </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Employment</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. Effective on the Effective Date, the Company shall employ Executive, and Executive shall be employed by the Company, for
the period and in the positions set forth in this <U>Section</U><U></U><U>&nbsp;1</U>, and subject to the other terms and conditions herein provided. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment</U>. The Company and Executive acknowledge that Executive&#146;s employment
is and shall continue to be <FONT STYLE="white-space:nowrap">&#147;at-will,&#148;</FONT> as defined under applicable law, and that Executive&#146;s employment with the Company may be terminated by either Party at any time for any or no reason
(subject to the notice requirements of <U>Section</U><U></U><U>&nbsp;3(b)</U>). This <FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> nature of Executive&#146;s employment shall remain unchanged during Executive&#146;s tenure as an
employee and may not be changed, except in an express writing signed by Executive and a duly authorized officer of the Company. If Executive&#146;s employment terminates for any reason, Executive shall not be entitled to any payments, benefits,
damages, award or compensation other than as provided in this Agreement or otherwise agreed to in writing by the Company or as provided by applicable law. The term of this Agreement (the &#147;<U>Term</U>&#148;) shall commence on the Effective Date
and end on the date this Agreement is terminated under <U>Section</U><U></U><U>&nbsp;3</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Positions and Duties</U>. During the
Term, Executive shall serve as Executive Chair of the Company, with such responsibilities, duties and authority normally associated with such position and as may from time to time be assigned to Executive by the Board of Directors of the Company or
an authorized committee thereof (in either case, the &#147;<U>Board</U>&#148;). Executive shall devote substantially all of Executive&#146;s working time and efforts to the business and affairs of the Company (which shall include service to its
affiliates, if applicable) and shall not engage in outside business activities (including serving on outside boards or committees) without the consent of the Board (which consent shall not be unreasonably withheld), provided that Executive shall be
permitted to (i)&nbsp;manage Executive&#146;s personal, financial and legal affairs, (ii)&nbsp;participate in trade associations, and (iii)&nbsp;serve on the board of directors of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> or <FONT STYLE="white-space:nowrap">tax-exempt</FONT> charitable organizations, in each case, subject to compliance with this Agreement and provided that
such activities do not materially interfere with Executive&#146;s performance of Executive&#146;s duties and responsibilities hereunder. Executive agrees to observe and comply with the rules and policies of the Company as adopted by the Company from
time to time, in each case, as amended from time to time, and as delivered or made available to Executive (collectively, the &#147;<U>Policies</U>&#148; and, each, a &#147;<U>Policy</U>&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Location</U>. The Executive shall be permitted to work from his home office in
Florida, provided that Executive shall be present at the principal offices of the Company as reasonably required to perform his duties or as requested by the Board. In addition, from time to time the Executive may be required to travel to other
locations in the proper conduct of his responsibilities under this Agreement. </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Compensation and Related Matters</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Annual Base Salary</U>. During the Term, Executive shall receive a base salary at a rate of $200,000 per annum, which shall be paid in
accordance with the customary payroll practices of the Company and shall be <FONT STYLE="white-space:nowrap">pro-rated</FONT> for partial years of employment. Such annual base salary shall be reviewed (and, may be increased and may not be decreased,
except to the extent described in <U>Section</U><U></U><U>&nbsp;7(f)(i)</U> below) from time to time by the Board (such annual base salary, as it may be adjusted from time to time, the &#147;<U>Annual Base Salary</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Bonus</U>. Unless otherwise determined by the Board, Executive will not be eligible to participate in the Company&#146;s annual or other
incentive bonus programs established by the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Equity Grants</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Subject to the approval of the Board, as soon as reasonably practicable following the Effective Date, Executive will be
granted an option to purchase 520,000 shares of the Company&#146;s common stock (the &#147;<U>Initial Option</U>&#148;) subject to the terms of a stock option award agreement in the form of Performance Stock Option Grant Notice and Stock Option
Agreement attached as <U>Exhibit</U><U></U><U>&nbsp;A</U> attached hereto (the &#147;<U>Option Agreement</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)
It is the intention of the Parties that the shares subject to the Initial Option represent approximately four percent (4%) of the Capitalization (as defined below) as of the Effective Date. In the event the shares subject to the Initial Option
represent less than 4% of the Capitalization of the Company following the closing of a bona fide equity financing of the Company following the date hereof and prior to March&nbsp;31, 2023 (the &#147;<U>Financing Closing</U>&#148;), subject to the
approval of the Board, as soon as reasonably practicable following the Financing Closing, the Company shall grant to Executive an additional option (&#147;<U>Additional Option</U>&#148;) to purchase common stock of the Company so that the shares
subject to the Initial Option plus the shares subject to such Additional Option equal not less than 4% of the Capitalization as of immediately following such Financing Closing, as determined by the Board. The exercise price of the Additional Option
will be equal to the fair market value per share of the common stock of the Company as of the date of grant (as determined in accordance with the terms of the equity plan under which the Additional Option is granted). The vesting and exercisability
terms of the Additional Option shall be the same as those set forth in the Option Agreement, with such changes as may be reasonably necessary to account for the different dates of grant. For the purposes hereof, the &#147;Capitalization&#148; means,
as of the Effective Date for purposes of the Initial Option and as of the Financing Closing for purposes of the Additional Option, the total number of shares of common stock of the Company outstanding (assuming the exercise or conversion of all
outstanding preferred stock and all options, warrants, and other securities of the Company that are exercisable for or convertible into shares of common stock of the Company). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Except as otherwise determined by the Board, Executive will not be
eligible to receive equity awards in 2022 and 2023 in connection with the Company&#146;s normal course annual equity award grant practice to executives and employees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Transaction Bonus</U>. In connection with a Change in Control in which the Market Capitalization of the Company equals or exceeds
$750&nbsp;million, Executive shall be entitled to a cash bonus in the amount of 1.0% of the Market Capitalization (the &#147;<U>Transaction Bonus</U>&#148;). The Transaction Bonus shall be payable within thirty (30)&nbsp;days after the completion of
the Change in Control transaction, subject to Executive&#146;s continued employment with the Company through the completion of the Change in Control transaction and execution, within thirty (30)&nbsp;days after the completion of the Change in
Control transaction, of a release of claims in favor of the Company in the form of the release attached as <U>Exhibit B</U> to this Agreement (subject to modifications for any specific dates or similar
<FONT STYLE="white-space:nowrap">non-substantive</FONT> amendments). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Benefits</U>. During the Term, Executive shall be eligible to
participate in employee benefit plans, programs and arrangements of the Company (including medical, dental and 401(k) plans), subject to the terms and eligibility requirements thereof and as such plans, programs and arrangements may be amended from
time to time. In no event shall Executive be eligible to participate in any severance plan or program of the Company, except as set forth in <U>Section</U><U></U><U>&nbsp;4</U> of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Vacation</U>. During the Term, Executive shall be entitled to paid personal leave in accordance with the Company&#146;s Policies. Any
vacation shall be taken at the reasonable and mutual convenience of the Company and Executive. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Business Expenses</U>. During the
Term, the Company shall reimburse Executive for all reasonable travel and other business expenses incurred by Executive in the performance of Executive&#146;s duties to the Company in accordance with the Company&#146;s expense reimbursement Policy.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Key Person Insurance</U>. At any time during the Term, the Company shall have the right (but not the obligation) to insure the life
of Executive for the Company&#146;s sole benefit. The Company shall have the right to determine the amount of insurance and the type of policy. Executive shall reasonably cooperate with the Company in obtaining such insurance by submitting to
physical examinations, by supplying all information reasonably required by any insurance carrier and by executing all necessary documents reasonably required by any insurance carrier, provided that any information provided to an insurance company or
broker shall not be provided to the Company without the prior written authorization of Executive. Executive shall incur no financial obligation by executing any required document and shall have no interest in any such policy. </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Termination</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both Executive&#146;s employment hereunder and the Term may be terminated by the Company or Executive, as applicable, without any breach of
this Agreement under the following circumstances: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Circumstances</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Death</I>. Executive&#146;s employment hereunder shall terminate upon Executive&#146;s death. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Disability</I>. If Executive has incurred a Disability, as defined below, the Company may terminate Executive&#146;s
employment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <I>Termination for Cause</I>. The Company may terminate
Executive&#146;s employment for Cause, as defined below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <I>Termination without Cause</I>. The Company may terminate
Executive&#146;s employment without Cause. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Resignation from the Company with Good Reason. </I>Executive may resign
Executive&#146;s employment with the Company with Good Reason, as defined below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <I>Resignation from the Company
without Good Reason</I>. Executive may resign Executive&#146;s employment with the Company for any reason other than Good Reason or for no reason. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Notice of Termination</U>. Any termination of Executive&#146;s employment by the Company or by Executive under this
<U>Section</U><U></U><U>&nbsp;3</U> (other than termination pursuant to <U>Section</U><U></U><U>&nbsp;3(a)(i))</U> shall be communicated by a written notice to the other Party hereto (i)&nbsp;indicating the specific termination provision in this
Agreement relied upon, (ii)&nbsp;setting forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive&#146;s employment under the provision so indicated, if applicable, and (iii)&nbsp;specifying a
Date of Termination (as defined below) which, if submitted by Executive, shall be at least thirty (30)&nbsp;days following the date of such notice (a &#147;<U>Notice of Termination</U>&#148;); <I>provided, however</I>, that in the event that
Executive delivers a Notice of Termination to the Company, the Company may, in its sole discretion, change the Date of Termination to any date that occurs following the date of the Company&#146;s receipt of such Notice of Termination and is prior to
the date specified in such Notice of Termination, but the termination will still be considered a resignation by Executive. A Notice of Termination submitted by the Company may provide for a Date of Termination on the date Executive receives the
Notice of Termination, or any date thereafter elected by the Company. The failure by either Party to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Cause or Good Reason shall not waive any right of
the Party hereunder or preclude the Party from asserting such fact or circumstance in enforcing the Party&#146;s rights hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<U>Company Obligations upon Termination</U>. Upon termination of Executive&#146;s employment pursuant to any of the circumstances listed in this <U>Section</U><U></U><U>&nbsp;3</U>, Executive (or Executive&#146;s estate) shall be entitled to receive
the sum of: (i)&nbsp;the portion of Executive&#146;s Annual Base Salary earned through the Date of Termination, but not yet paid to Executive; (ii)&nbsp;any expense reimbursements owed to Executive pursuant to <U>Section</U><U></U><U>&nbsp;2(g)</U>;
and (iii)&nbsp;any amount accrued and arising from Executive&#146;s participation in, or benefits accrued under any employee benefit plans, programs or arrangements, which amounts shall be payable in accordance with the terms and conditions of such
employee benefit plans, programs or arrangements (collectively, the &#147;<U>Company Arrangements</U>&#148;). Except as otherwise expressly required by law (e.g., the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended
(&#147;<U>COBRA</U>&#148;)) or as specifically provided herein, all of Executive&#146;s rights to salary, severance, benefits, bonuses and other compensatory amounts hereunder (if any) shall cease upon the termination of Executive&#146;s employment
hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Deemed Resignation</U>. Upon termination of Executive&#146;s employment for any reason, Executive shall be deemed to
have resigned from all offices and directorships, if any, then held with the Company or any of its subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Severance Payments</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination for Cause, or Termination Upon Death, Disability or Resignation from the Company Without Good Reason</U>. If
Executive&#146;s employment shall terminate as a result of Executive&#146;s death pursuant to <U>Section</U><U></U><U>&nbsp;3(a)(i)</U>, as a result of Disability pursuant to <U>Section</U><U></U><U>&nbsp;3(a)(ii)</U>, for Cause pursuant to
<U>Section</U><U></U><U>&nbsp;3(a)(iii)</U> or for Executive&#146;s resignation from the Company without Good Reason pursuant to <U>Section</U><U></U><U>&nbsp;3(a)(iv)</U>, then Executive shall not be entitled to any severance payments or benefits,
except as provided in <U>Section</U><U></U><U>&nbsp;3(c)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination without Cause, or Resignation from the Company with Good
Reason</U>. If Executive&#146;s employment terminates without Cause pursuant to <U>Section</U><U></U><U>&nbsp;3(a)(iv)</U>, or pursuant to <U>Section</U><U></U><U>&nbsp;3(a)(v)</U> due to Executive&#146;s resignation with Good Reason, then, subject
to Executive signing a release agreement in the form of Exhibit B (the &#147;<U>Release</U>&#148;) hereto on or before the twenty-first (21st) day following Executive&#146;s receipt of the Release from the Company following Executive&#146;s
Separation from Service (as defined below), which shall be provided within ten (10)&nbsp;days of the date of the Separation from Service, or in the event that such Separation from Service is &#147;in connection with an exit incentive or other
employment termination program&#148; (as such phrase is defined in the Age Discrimination in Employment Act of 1967, as amended) on or before the forty-fifth (45th) day following Executive&#146;s receipt of the Release from the Company, as the case
may be, and provided that Executive does not revoke, the Release, and Executive&#146;s continued compliance with <U>Section</U><U></U><U>&nbsp;5</U>, Executive shall receive, in addition to payments and benefits set forth in
<U>Section</U><U></U><U>&nbsp;3(c)</U>, the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) an amount in cash equal to one times the Annual Base Salary,
payable in the form of salary continuation in regular installments over the <FONT STYLE="white-space:nowrap">12-month</FONT> period following the date of Executive&#146;s Separation from Service (the &#147;<U>Severance Period</U>&#148;) in
accordance with the Company&#146;s normal payroll practices; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) if Executive timely elects to receive continued medical,
dental or vision coverage under one or more of the Company&#146;s group medical, dental or vision plans pursuant to COBRA, then the Company shall directly pay, or reimburse Executive for, the COBRA premiums for Executive and Executive&#146;s covered
dependents under such plans, less the amount Executive would have had to pay to receive such coverage as an active employee based on the cost sharing levels in effect on the Date of Termination, during the period commencing on Executive&#146;s
Separation from Service and ending upon the earliest of (X)&nbsp;the last day of the Severance Period, (Y)&nbsp;the date that Executive and/or Executive&#146;s covered dependents become no longer eligible for COBRA or (Z)&nbsp;the date Executive
becomes eligible to receive medical, dental or vision coverage, as applicable, from a subsequent employer (and Executive agrees to promptly notify the Company of such eligibility). Notwithstanding the foregoing, if the Company determines in its sole
discretion that it cannot provide the foregoing benefit without potentially violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act) or incurring an excise tax, the Company shall in lieu thereof
provide to Executive a taxable monthly payment in an amount equal to the monthly COBRA premium that Executive would be required to pay to continue Executive&#146;s and Executive&#146;s covered dependents&#146; group health coverage in effect on the
Date of Termination (which amount shall be based on the premium for the first month of COBRA coverage), less the amount Executive would have had to pay to receive group health coverage as an active employee for Executive and his or her covered
dependents based on the cost sharing levels in effect on the Date of Termination, which payments shall be made regardless of whether Executive elects COBRA continuation coverage and shall commence in the month following the month in which the Date
of Termination occurs and shall end on the earliest of (X)&nbsp;the last day of the Severance Period, (Y)&nbsp;the date that Executive and/or Executive&#146;s covered dependents become no longer eligible for COBRA or (Z)&nbsp;the date Executive
becomes eligible to receive healthcare coverage from a subsequent employer (and Executive agrees to promptly notify the Company of such eligibility); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) any vested and exercisable options (or options that become vested and
exercisable under any governing grant agreement or document following the Date of Termination, including without limitation the Initial Option and the Additional Option), under the equity plans maintained by the Company (any such plan, an
&#147;<U>Equity Plan</U>&#148;) held by Executive as of the Date of Termination, will remain outstanding and exercisable for twelve (12)&nbsp;months from the Date of Termination (provided that (A)&nbsp;in no event will any such option remain
outstanding past the final expiration date set forth in the applicable option award agreement, and (B)&nbsp;all such options will in all events remain subject to earlier termination in connection with a corporate transaction or event in accordance
with the applicable option award agreement and Equity Plan). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Change in Control</U>. In lieu of the payments and benefits set forth
in <U>Section</U><U></U><U>&nbsp;4</U><U>(b)</U>, in the event Executive&#146;s employment terminates without Cause pursuant to <U>Section</U><U></U><U>&nbsp;3(a)(iv)</U>, or due to Executive&#146;s resignation with Good Reason pursuant to
<U>Section</U><U></U><U>&nbsp;3(a)(v)</U>, in either case, within three (3)&nbsp;months prior or twelve (12)&nbsp;months following the date of a Change in Control, subject to Executive signing on or before the twenty-first (21st) day following
Executive&#146;s receipt of a Release from the Company following such Separation from Service, which shall be provided within ten (10)&nbsp;days of the date of the Separation from Service, or in the event that such Separation from Service is
&#147;in connection with an exit incentive or other employment termination program&#148; (as such phrase is defined in the Age Discrimination in Employment Act of 1967, as amended) on or before the forty-fifth (45th) day following Executive&#146;s
receipt of a Release from the Company following such Separation from Service, and not revoking the Release, and Executive&#146;s continued compliance with <U>Section</U><U></U><U>&nbsp;5</U>, Executive shall receive, in addition to the payments and
benefits set forth in <U>Section</U><U></U><U>&nbsp;3(c)</U>, the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) an amount in cash equal to 1.5 times the
Annual Base Salary, payable in equal installments over the <FONT STYLE="white-space:nowrap">18-month</FONT> period following the date of Executive&#146;s Separation from Service (the &#147;<U>CIC Severance Period</U>&#148;) in accordance with the
Company&#146;s normal payroll practices; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the benefits set forth in <U>Section</U><U></U><U>&nbsp;4(b)(ii)</U>,
provided that the &#147;Severance Period&#148; will mean the CIC Severance Period; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) all unvested equity or
equity-based awards held by Executive under any Company equity compensation plans that vest solely based on the passage of time shall immediately become 100% vested (for the avoidance of doubt, with any such awards that vest in whole or in part
based on the attainment of performance-vesting conditions being governed by the terms of the applicable award agreement); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) the benefits set forth in <U>Section</U><U></U><U>&nbsp;4(b)(iii)</U>; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) The Transaction Bonus, provided that the conditions for issuance of the Transaction Bonus are otherwise satisfied in
accordance with <U>Section</U><U></U><U>&nbsp;2(d)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Survival</U>. Notwithstanding anything to the contrary in this Agreement,
the provisions of <U>Sections 5</U> through <U>9</U> will survive the termination of Executive&#146;s employment and the termination of the Term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Restrictive Covenants</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a condition to the effectiveness of this Agreement, Executive will have executed and delivered to the Company no later than
contemporaneously herewith the Employee Proprietary Information and Inventions Assignment Agreement, attached as <U>Exhibit C</U> (together, the &#147;<U>Restrictive Covenant Agreement</U>&#148;). Executive agrees to abide by the terms of the
Restrictive Covenant Agreement, which are hereby incorporated by reference into this Agreement. Executive acknowledges that the provisions of the Restrictive Covenant Agreement will survive the termination of Executive&#146;s employment and the
termination of the Term for the periods set forth in the Restrictive Covenant Agreement. </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Assignment and Successors</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may assign its rights and obligations under this Agreement to any of its affiliates or to any successor to all or substantially all
of the business or the assets of the Company (by merger or otherwise), and may assign or encumber this Agreement and its rights hereunder as security for indebtedness of the Company and its affiliates. This Agreement shall be binding upon and inure
to the benefit of the Company, Executive and their respective successors, assigns, personnel and legal representatives, executors, administrators, heirs, distributees, devisees, and legatees, as applicable. None of Executive&#146;s rights or
obligations may be assigned or transferred by Executive, other than Executive&#146;s rights to payments hereunder, which may be transferred only by will or operation of law. Notwithstanding the foregoing, Executive shall be entitled, to the extent
permitted under applicable law and applicable Company Arrangements, to select and change a beneficiary or beneficiaries to receive compensation hereunder following Executive&#146;s death by giving written notice thereof to the Company. </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Certain Definitions</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Cause</U>. The Company shall have &#147;Cause&#148; to terminate Executive&#146;s employment hereunder upon: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Executive&#146;s willful refusal to (A)&nbsp;substantially perform the material duties associated with Executive&#146;s
position with the Company or (B)&nbsp;carry out the reasonable and lawful instructions of the Board concerning material duties or actions consistent with the Executive&#146;s position with the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Executive&#146;s willful breach of a material provision of this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Executive&#146;s conviction, plea of no contest, plea of <I>nolo contendere</I>, or imposition of unadjudicated probation
for any felony or crime involving moral turpitude; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Executive&#146;s unlawful use (including being under the
influence) or possession of illegal drugs on the Company&#146;s (or any of its affiliate&#146;s) premises or while performing Executive&#146;s duties and responsibilities under this Agreement; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Executive&#146;s commission of fraud, embezzlement, misappropriation, willful misconduct, or breach of fiduciary duty
against the Company or any of its affiliates; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>provided</I>, <I>however</I>, no Cause will have occurred unless and until the Company
has: (A)&nbsp;provided Executive, within sixty (60)&nbsp;days of the Company&#146;s knowledge of the occurrence of the facts and circumstances underlying the Cause event, written notice stating with specificity the applicable facts and circumstances
underlying such finding of Cause; (B)&nbsp;that with respect to clause (i)&nbsp;or (ii) of this definition and to the extent reasonably susceptible to cure, provided Executive with an opportunity to cure the same within thirty (30)&nbsp;days after
the receipt of such notice; and (C)&nbsp;Executive shall have failed to so cure within such period (if any). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Change in Control</U>. &#147;Change in Control&#148; shall have the meaning set forth
in the Lyra Therapeutics, Inc. 2020 Incentive Award Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Code</U>. &#147;Code&#148; shall mean the Internal Revenue Code of 1986,
as amended, and the regulations and guidance promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Date of Termination</U>. &#147;Date of Termination&#148; shall
mean (i)&nbsp;if Executive&#146;s employment is terminated by Executive&#146;s death, the date of Executive&#146;s death; or (ii)&nbsp;if Executive&#146;s employment is terminated pursuant to <U>Section</U><U></U><U>&nbsp;3(a)(ii) &#150; (vi)</U>
either the date indicated in the Notice of Termination or the date specified by the Company pursuant to <U>Section</U><U></U><U>&nbsp;3(b)</U>, whichever is earlier. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Disability</U>. &#147;Disability&#148; shall mean, at any time the Company or any of its affiliates sponsors a long-term disability plan
for the Company&#146;s employees, &#147;disability&#148; as defined in such long-term disability plan for the purpose of determining a participant&#146;s eligibility for benefits, <I>provided, however</I>, if the long-term disability plan contains
multiple definitions of disability, &#147;Disability&#148; shall refer to that definition of disability which, if Executive qualified for such disability benefits, would provide coverage for the longest period of time. The determination of whether
Executive has a Disability shall be made by the person or persons required to make disability determinations under the long-term disability plan. At any time the Company does not sponsor a long-term disability plan for its employees,
&#147;Disability&#148; shall mean Executive&#146;s inability to perform, with or without reasonable accommodation, the essential functions of Executive&#146;s positions hereunder for a total of six months during any twelve-month period as a result
of incapacity due to mental or physical illness as determined by a physician selected by the Company or its insurers and acceptable to Executive or Executive&#146;s legal representative, with such agreement as to acceptability not to be unreasonably
withheld or delayed. Any refusal by Executive to submit to a medical examination for the purpose of determining Disability shall be deemed to constitute conclusive evidence of Executive&#146;s Disability. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Good Reason</U>. For the sole purpose of determining Executive&#146;s right to severance payments and benefits as described above,
Executive&#146;s resignation will be with &#147;Good Reason&#148; if Executive resigns within ninety (90)&nbsp;days after any of the following events, unless Executive consents in writing to the applicable event: (i)&nbsp;a reduction in
Executive&#146;s Annual Base Salary, other than a reduction of ten percent (10%) or less of Executive&#146;s Annual Base Salary implemented as part of an across the board, proportionate reduction of base salaries for other members of the
Company&#146;s senior management team, (ii)&nbsp;a decrease in Executive&#146;s authority or areas of responsibility as are commensurate with Executive&#146;s title or position with the Company, (iii)&nbsp;the relocation of Executive&#146;s primary
office to a location more than fifty (50)&nbsp;miles from the Executive&#146;s primary office as of the date of this Agreement; or (iv)&nbsp;the Company&#146;s breach of a material provision of this Agreement, including the failure of the Board (or
a committee thereof) to approve the Initial Option or the Additional Option, as the case may be, in accordance with the terms hereof. Notwithstanding the foregoing, no Good Reason will have occurred unless and until Executive has: (a)&nbsp;provided
the Company, within sixty (60)&nbsp;days of Executive&#146;s knowledge of the occurrence of the facts and circumstances underlying the Good Reason event, written notice stating with specificity the applicable facts and circumstances underlying such
finding of Good Reason; (b)&nbsp;provided the Company with an opportunity to cure the same within thirty (30)&nbsp;days after the receipt of such notice; and (c)&nbsp;the Company shall have failed to so cure within such period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Market Capitalization</U>. &#147;Market Capitalization&#148; shall mean an amount
equal to the product of (i)&nbsp;the cash price per share of the Company&#146;s common stock (a &#147;<U>Share</U>&#148;) paid by an acquiror in connection with a Change in Control, or, if the consideration in the Change in Control transaction is
payable in a form other than a fixed amount of cash per Share, the closing price per Share on the last trading day preceding the closing date of the Change in Control, and (ii)&nbsp;the number of Shares outstanding as of immediately prior to the
Change in Control. </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Parachute Payments</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding any other provisions of this Agreement or any Company equity plan or agreement, in the event that any payment or benefit
by the Company or otherwise to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (all such payments and benefits, including the payments and benefits under
<U>Section</U><U></U><U>&nbsp;4</U> hereof, being hereinafter referred to as the &#147;<U>Total Payments</U>&#148;), would be subject (in whole or in part) to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<U>Excise
Tax</U>&#148;), then the Total Payments shall be reduced (in the order provided in <U>Section</U><U></U><U>&nbsp;8(b)</U>) to the minimum extent necessary to avoid the imposition of the Excise Tax on the Total Payments, but only if (i)&nbsp;the net
amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local income and employment taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal
exemptions attributable to such reduced Total Payments), is greater than or equal to (ii)&nbsp;the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income and employment taxes
on such Total Payments and the amount of the Excise Tax to which Executive would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such
unreduced Total Payments). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Total Payments shall be reduced in the following order: (i)&nbsp;reduction on a <FONT
STYLE="white-space:nowrap">pro-rata</FONT> basis of any cash severance payments that are exempt from Section&nbsp;409A of the Code (&#147;<U>Section</U><U></U><U>&nbsp;409A</U>&#148;), (ii) reduction on a
<FONT STYLE="white-space:nowrap">pro-rata</FONT> basis of any <FONT STYLE="white-space:nowrap">non-cash</FONT> severance payments or benefits that are exempt from Section&nbsp;409A, (iii)&nbsp;reduction on a
<FONT STYLE="white-space:nowrap">pro-rata</FONT> basis of any other payments or benefits that are exempt from Section&nbsp;409A and (iv)&nbsp;reduction of any payments or benefits otherwise payable to Executive on a
<FONT STYLE="white-space:nowrap">pro-rata</FONT> basis or such other manner that complies with Section&nbsp;409A; provided, in case of clauses (ii), (iii) and (iv), that reduction of any payments attributable to the acceleration of vesting of
Company equity awards shall be first applied to Company equity awards that would otherwise vest last in time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) All determinations
regarding the application of this <U>Section</U><U></U><U>&nbsp;8</U> shall be made by an accounting firm or consulting group with experience in performing calculations regarding the applicability of Section&nbsp;280G of the Code and the Excise Tax
selected by the Company and reasonably acceptable to the Executive (the &#147;<U>Independent Advisors</U>&#148;). For purposes of determinations, no portion of the Total Payments shall be taken into account which, in the opinion of the Independent
Advisors, (i)&nbsp;does not constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G(b)(2) of the Code (including by reason of Section&nbsp;280G(b)(4)(A) of the Code) or (ii)&nbsp;constitutes reasonable compensation for
services actually rendered, within the meaning of Section&nbsp;280G(b)(4)(B) of the Code, in excess of the &#147;base amount&#148; (as defined in Section&nbsp;280G(b)(3) of the Code) allocable to such reasonable compensation. The costs of obtaining
such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) In the event it is later determined that a greater reduction in the Total Payments should have been made to implement the objective and
intent of this <U>Section</U><U></U><U>&nbsp;8</U>, the excess amount shall be returned promptly by Executive to the Company. In the event it is later determined that a lesser reduction in the Total Payments should have been made to implement the
objective and intent of this <U>Section</U><U></U><U>&nbsp;8</U>, the underpayment amount shall be paid promptly by the Company to the Executive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Miscellaneous Provisions</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Governing Law</U>. This Agreement shall be governed, construed, interpreted and enforced in accordance with its express terms, and
otherwise in accordance with the substantive laws of the Commonwealth of Massachusetts without reference to the principles of conflicts of law of the Commonwealth of Massachusetts or any other jurisdiction that would result in the application of the
laws of a jurisdiction other than the Commonwealth of Massachusetts, and where applicable, the laws of the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Validity</U>. The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Notices</U>. Any notice, request, claim, demand, document and other communication hereunder to any Party shall be effective upon receipt
(or refusal of receipt) and shall be in writing and delivered personally or sent by facsimile or certified or registered mail, postage prepaid, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) If to the Company, to the Chief Financial Officer of the Company at the Company&#146;s headquarters, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) If to Executive, to the last address that the Company has in its personnel records for Executive, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) At any other address as any Party shall have specified by notice in writing to the other Party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Counterparts</U>. This Agreement may be executed in several counterparts, each of which shall be deemed to be an original, but all of
which together will constitute one and the same Agreement. Signatures delivered by facsimile or PDF shall be deemed effective for all purposes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Entire Agreement</U>. The terms of this Agreement, and the Restrictive Covenant Agreement incorporated herein by reference as set forth
in <U>Section</U><U></U><U>&nbsp;5</U>, are intended by the Parties to be the final expression of their agreement with respect to the subject matter hereof and supersede all prior understandings and agreements, whether written or oral, including any
prior employment offer letter or employment agreement between Executive and the Company. The Parties further intend that this Agreement shall constitute the complete and exclusive statement of their terms and that no extrinsic evidence whatsoever
may be introduced in any judicial, administrative or other legal proceeding to vary the terms of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Amendments;
Waivers</U>. This Agreement may not be modified, amended or terminated except by an instrument in writing, signed by Executive and a duly authorized officer of Company. By an instrument in writing similarly executed, Executive or a duly authorized
officer of the Company may waive compliance by the other Party with any specifically identified provision of this Agreement that such other Party was or is obligated to comply with or perform; <I>provided</I>, <I>however</I>, that such waiver shall
not operate as a waiver of, or estoppel with respect to, any other or subsequent failure. No failure to exercise and no delay in exercising any right, remedy or power hereunder will preclude any other or further exercise of any other right, remedy
or power provided herein or by law or in equity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Construction</U>. This Agreement shall be deemed drafted equally by both the Parties.
Its language shall be construed as a whole and according to its fair meaning. Any presumption or principle that the language is to be construed against any Party shall not apply. The headings in this Agreement are only for convenience and are not
intended to affect construction or interpretation. Any references to paragraphs, subparagraphs, sections or subsections are to those parts of this Agreement, unless the context clearly indicates to the contrary. Also, unless the context clearly
indicates to the contrary, (i)&nbsp;the plural includes the singular and the singular includes the plural; (ii) &#147;and&#148; and &#147;or&#148; are each used both conjunctively and disjunctively; (iii) &#147;any,&#148; &#147;all,&#148;
&#147;each,&#148; or &#147;every&#148; means &#147;any and all&#148; and &#147;each and every&#148;; (iv) &#147;includes&#148; and &#147;including&#148; are each &#147;without limitation&#148;; (v) &#147;herein,&#148; &#147;hereof,&#148;
&#147;hereunder&#148; and other similar compounds of the word &#147;here&#148; refer to the entire Agreement and not to any particular paragraph, subparagraph, section or subsection; and (vi)&nbsp;all pronouns and any variations thereof shall be
deemed to refer to the masculine, feminine, neuter, singular or plural as the identity of the entities or persons referred to may require. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Arbitration</U>. Any controversy, claim or dispute arising out of or relating to this Agreement, shall be settled solely and exclusively
by a binding arbitration process administered by JAMS/Endispute in Boston, Massachusetts. Such arbitration shall be conducted in accordance with the then-existing JAMS/Endispute Employment Rules of Practice and Procedure, with the following
exceptions if in conflict one arbitrator who is a retired judge shall be chosen by JAMS/Endispute. Each Party shall bear its own attorney&#146;s fees and expenses; provided that the arbitrator may assess the prevailing Party&#146;s fees and costs
against the <FONT STYLE="white-space:nowrap">non-prevailing</FONT> Party as part of the arbitrator&#146;s award. The Parties agree to abide by all decisions and awards rendered in such proceedings. Such decisions and awards rendered by the
arbitrator shall be final and conclusive. All such controversies, claims or disputes shall be settled in this manner in lieu of any action at law or equity; provided, however, that nothing in this subsection shall be construed as precluding the
bringing of an action for injunctive relief or specific performance as provided in this Agreement or the Restrictive Covenant Agreement. This dispute resolution process and any arbitration hereunder shall be confidential and neither any Party nor
the neutral arbitrator shall disclose the existence, contents or results of such process without the prior written consent of all Parties, except where necessary or compelled in a court to enforce this arbitration provision or an award from such
arbitration or otherwise in a legal proceeding. If JAMS/Endispute no longer exists or is otherwise unavailable, the Parties agree that the American Arbitration Association (&#147;<U>AAA</U>&#148;) shall administer the arbitration in accordance with
its then-existing rules as modified by this subsection. In such event, all references herein to JAMS/Endispute shall mean AAA. Notwithstanding the foregoing, Executive and the Company each have the right to resolve any issue or dispute over
intellectual property rights by court action instead of arbitration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Enforcement</U>. If any provision of this Agreement is held to
be illegal, invalid or unenforceable under present or future laws effective during the Term, such provision shall be fully severable; this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never
comprised a portion of this Agreement; and the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance from this Agreement.
Furthermore, in lieu of such illegal, invalid or unenforceable provision there shall be added automatically as part of this Agreement a provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and be
legal, valid and enforceable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Withholding</U>. The Company shall be entitled to withhold from any amounts payable under this
Agreement any federal, state, local or foreign withholding or other taxes or charges which the Company is required to withhold. The Company shall be entitled to rely on the advice of counsel if any questions as to the amount or requirement of
withholding shall arise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Section</U><U></U><U>&nbsp;409A</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>General.</I> The intent of the Parties is that the payments and benefits under this Agreement comply with or be exempt
from Section&nbsp;409A and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith. The Company and the Executive agree that they will execute any and all amendments to this Agreement
permitted under applicable law as they mutually agree in good faith may be necessary to ensure compliance with the distribution provisions of Section&nbsp;409A of the Code or as otherwise needed to ensure that this Agreement complies with
Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Separation from Service. </I>Notwithstanding anything in this Agreement to the
contrary, any compensation or benefits payable under this Agreement that is designated under this Agreement as payable upon Executive&#146;s termination of employment shall be payable only upon Executive&#146;s &#147;separation from service&#148;
with the Company within the meaning of Section&nbsp;409A (a &#147;<U>Separation from Service</U>&#148;) and, except as provided below, any such compensation or benefits described in <U>Section</U><U></U><U>&nbsp;4</U> shall not be paid, or, in the
case of installments, shall not commence payment, until the sixtieth (60th) day following Executive&#146;s Separation from Service (the &#147;<U>First Payment Date</U>&#148;). Any installment payments that would have been made to Executive during
the sixty (60)&nbsp;day period immediately following Executive&#146;s Separation from Service but for the preceding sentence shall be paid to Executive on the First Payment Date and the remaining payments shall be made as provided in this Agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <I>Specified Employee.</I> Notwithstanding anything in this Agreement to the contrary, if Executive is deemed by the
Company at the time of Executive&#146;s Separation from Service to be a &#147;specified employee&#148; for purposes of Section&nbsp;409A, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this
Agreement is required in order to avoid a prohibited distribution under Section&nbsp;409A, such portion of Executive&#146;s benefits shall not be provided to Executive prior to the earlier of (i)&nbsp;the expiration of the <FONT
STYLE="white-space:nowrap">six-month</FONT> period measured from the date of Executive&#146;s Separation from Service with the Company or (ii)&nbsp;the date of Executive&#146;s death. Upon the first business day following the earlier of expiration
of the applicable <FONT STYLE="white-space:nowrap">six-month</FONT> delay period or the date of Executive&#146;s death, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to Executive (or Executive&#146;s estate or
beneficiaries), and any remaining payments due to Executive under this Agreement shall be paid as otherwise provided herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <I>Expense Reimbursements. </I>To the extent that any reimbursements under this Agreement are subject to
Section&nbsp;409A, any such reimbursements payable to Executive shall be paid to Executive no later than December&nbsp;31 of the year following the year in which the expense was incurred. The Executive will submit Executive&#146;s reimbursement
request promptly following the date the expense is incurred, and the amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year, other than medical expenses referred to in
Section&nbsp;105(b) of the Code. Executive&#146;s right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Installments.</I> Executive&#146;s right to receive any installment payments under this Agreement, including without
limitation any continuation salary payments that are payable on Company payroll dates, shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall at all times be considered a separate
and distinct payment as permitted under Section&nbsp;409A. Except as otherwise permitted under Section&nbsp;409A, no payment hereunder shall be accelerated or deferred unless such acceleration or deferral would not result in additional tax or
interest pursuant to Section&nbsp;409A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Executive Acknowledgement</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive acknowledges that Executive has read and understands this Agreement, is fully aware of its legal effect, has not acted in reliance
upon any representations or promises made by the Company other than those contained in writing herein, and has entered into this Agreement freely based on Executive&#146;s own judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Agreement on the date first written
above.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LYRA THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maria Palasis, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Maria Palasis, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Harlan Waksal, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Harlan Waksal, M.D.</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Employment Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Option Agreement </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[See
Exhibit 10.4] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Separation Agreement and Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Separation Agreement and Release ( this &#147;<U>Release</U>&#148;) is made by and between Harlan Waksal (&#147;<U>Executive</U>&#148;)
and Lyra Therapeutics, Inc. (the &#147;<U>Company</U>&#148;) (collectively referred to as the &#147;<U>Parties</U>&#148; or individually referred to as a &#147;<U>Party</U>&#148;). Capitalized terms used but not defined in this Release shall have
the meanings set forth in the Employment Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties have previously entered into that certain
Employment Agreement, dated as of Februrary 16, 2022 (the &#147;<U>Employment Agreement</U>&#148;) and that certain Employee Proprietary Information and Inventions Assignment Agreement, dated as of Februrary 16, 2022 (the &#147;<U>Restrictive
Covenant Agreement</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with Executive&#146;s termination of employment with the Company or a
subsidiary or affiliate of the Company effective ________, 20__, the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions and demands that Executive may have against the Company and any of the
Releasees as defined below, including, but not limited to, any and all claims arising out of or in any way related to Executive&#146;s employment with or separation from the Company or its subsidiaries or affiliates but, for the avoidance of doubt,
nothing herein will be deemed to release any rights or remedies in connection with Executive&#146;s ownership of vested equity securities of the Company, vested benefits or Executive&#146;s right to indemnification by the Company or any of its
affiliates pursuant to contract or applicable law (collectively, the &#147;<U>Retained Claims</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in
consideration of the severance payments and benefits described in Section&nbsp;4 of the Employment Agreement, which, pursuant to the Employment Agreement, are conditioned on Executive&#146;s execution and
<FONT STYLE="white-space:nowrap">non-revocation</FONT> of this Release, and in consideration of the mutual promises made herein, the Company and Executive hereby agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Severance Payments and Benefits; Salary and Benefits</U>. The Company agrees to provide Executive with the severance payments and
benefits described in Section [4(b)][4(c)] of the Employment Agreement, payable at the times set forth in, and subject to the terms and conditions of, the Employment Agreement. In addition, to the extent not already paid, and subject to the terms
and conditions of the Employment Agreement, the Company shall pay or provide to Executive all other payments or benefits described in Section&nbsp;3(c) of the Employment Agreement, subject to and in accordance with the terms thereof. The severance
payments and benefits described in Section [4(b)][4(c)] of the Employment Agreement shall be provided in lieu of any Garden Leave payment (as such term is used in the Restrictive Covenants Agreement) and Executive will not be eligible to receive any
Garden Leave payment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Release of Claims</U>. Executive agrees that, other than with respect to the Retained Claims, the foregoing
consideration represents settlement in full of all outstanding obligations owed to Executive by the Company, any of its direct or indirect subsidiaries and affiliates and any of its or their current and former officers, directors, equityholders,
managers, employees, agents, investors, attorneys, shareholders, administrators, affiliates, benefit plans, plan administrators, insurers, trustees, divisions, subsidiaries, predecessor and successor corporations and assigns (collectively, the
&#147;<U>Releasees</U>&#148;). Executive, on Executive&#146;s own behalf and on behalf of any of Executive&#146;s affiliated companies or entities and any of their respective heirs, family members, executors, agents and assigns, other than with
respect to the Retained Claims, hereby and forever releases the Releasees from, and agrees not to sue concerning, or in any manner to institute, prosecute or pursue, any claim, complaint, charge, duty, obligation or cause of action relating to any
matters of any kind, whether presently known or unknown, suspected or unsuspected, that Executive may possess against any of the Releasees arising from any omissions, acts, facts or damages that have occurred up until and including the date
Executive signs this Release, including, without limitation: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) any and all claims relating to or arising from Executive&#146;s employment or service
relationship with the Company or any of its direct or indirect subsidiaries or affiliates and the termination of that relationship; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
any and all claims relating to, or arising from, Executive&#146;s right to purchase, or actual purchase of any shares of stock or other equity interests of the Company or any of its affiliates, including, without limitation, any claims for fraud,
misrepresentation, breach of fiduciary duty, breach of duty under applicable state law and securities fraud under any state or federal law; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) any and all claims for wrongful discharge of employment; termination in violation of public policy; discrimination; harassment;
retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent or intentional infliction of emotional distress; fraud; negligent or intentional
misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment;
conversion; and disability benefits; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) any and all claims for violation of any federal, state or municipal statute, including, but not
limited to, Title VII of the Civil Rights Act of 1964; the Civil Rights Act of 1991; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act; the Fair Labor Standards Act; the Fair Credit Reporting Act; the Age
Discrimination in Employment Act of 1967; the Older Workers Benefit Protection Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining Notification Act; the Family and Medical Leave Act; the Sarbanes-Oxley Act
of 2002; the Massachusetts Fair Employment Practices Act, M.G.L. c. 151B, &#167; 1 <U>et seq</U>.; the Massachusetts Civil Rights Act, M.G.L. c. 12, &#167;&#167; IIH and 111; the Massachusetts Equal Rights Act, M.G.L. c. 93, &#167; 102 and M.G.L. c.
214, &#167; IC; the Massachusetts Labor and Industries Act, M.G.L. c. 149, &#167; 1 <U>et seq</U>.; the Massachusetts Privacy Act, M.G.L. c. 214, &#167; 1B; and the Massachusetts Maternity Leave Act, M.G.L. c. 49, &#167; 105D; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) any and all claims for violation of the federal or any state constitution; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) any and all claims arising out of any other laws and regulations relating to employment or employment discrimination; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) any claim for any loss, cost, damage or expense arising out of any dispute over the <FONT STYLE="white-space:nowrap">non-withholding</FONT>
or other tax treatment of any of the proceeds received by Executive as a result of this Release; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) any and all claims arising out of the
wage and hour and wage payments laws and regulations of the state or states in which Executive has provided service to the Company or any of its affiliates (including without limitation the Massachusetts Payment of Wages Law); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) any and all claims for attorneys&#146; fees and costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive agrees that the release set forth in this section shall be and remain in effect in all respects as
a complete general release as to the matters released. This Release does not release claims that cannot be released as a matter of law, including, but not limited to, Executive&#146;s right to report possible violations of federal law or regulation
to any governmental agency or entity in accordance with the provisions of and rules promulgated under Section&nbsp;21F of the Securities Exchange Act of 1934 or Section&nbsp;806 of the Sarbanes-Oxley Act of 2002, or any other whistleblower
protection provisions of state or federal law or regulation and any right to receive an award for information provided thereunder, Executive&#146;s right to file a charge with or participate in a charge by the Equal Employment Opportunity
Commission, or any other local, state or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, against the Company for discrimination (with the understanding that Executive&#146;s
release of claims herein bars Executive from recovering such monetary relief from the Company or any Releasee for any alleged discriminatory treatment), claims for unemployment compensation or any state disability insurance benefits pursuant to the
terms of applicable state law, claims to continued participation in certain of the Company&#146;s group benefit plans pursuant to the terms and conditions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, claims to any
benefit entitlements vested as the date of separation of Executive&#146;s employment, pursuant to written terms of any employee benefit plan of the Company or its affiliates, any claims that Executive may have by virtue of Executive&#146;s status as
a shareholder in the Company, and Executive&#146;s right under applicable law and any Retained Claims. This Release further does not release claims for breach of Section&nbsp;3(c) or Section&nbsp;4 of the Employment Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Acknowledgment of Waiver of Claims under ADEA</U>. Executive understands and acknowledges that Executive is waiving and releasing any
rights Executive may have under the Age Discrimination in Employment Act of 1967 (&#147;<U>ADEA</U>&#148;), and that this waiver and release is knowing and voluntary. Executive understands and agrees that this waiver and release does not apply to
any rights or claims that may arise under the ADEA after the date Executive signs this Release. Executive understands and acknowledges that the consideration given for this waiver and release is in addition to anything of value to which Executive
was already entitled. Executive further understands and acknowledges that Executive has been advised by this writing that: (a)&nbsp;Executive should consult with an attorney prior to executing this Release; (b)&nbsp;Executive has <FONT
STYLE="white-space:nowrap">[twenty-one</FONT> (21)][forty-five (45)] days within which to consider this Release following Executive&#146;s receipt of this Release from the Company, and the Parties agree that such time period to review this Release
shall not be extended upon any material or immaterial changes to this Release; (c)&nbsp;Executive has seven (7)&nbsp;business days following Executive&#146;s execution of this Release to revoke this Release pursuant to written notice to the General
Counsel of the Company; (d)&nbsp;this Release shall not be effective until after the revocation period has expired; and (e)&nbsp;nothing in this Release prevents or precludes Executive from challenging or seeking a determination in good faith of the
validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties or costs for doing so, unless specifically authorized by federal law. In the event Executive signs this Release and returns it to the Company in less than
the <FONT STYLE="white-space:nowrap">[twenty-one</FONT> (21)][forty-five (45)] day period identified above, Executive hereby acknowledges that Executive has freely and voluntarily chosen to waive the time period allotted for considering this
Release. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Restrictive Covenants</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Executive acknowledges and agrees that the restrictive covenants and other post-termination obligations set forth in the Restrictive
Covenant Agreement, including without limitation Executive&#146;s obligations relating to <FONT STYLE="white-space:nowrap">non-use</FONT> and <FONT STYLE="white-space:nowrap">non-disclosure</FONT> of confidential information, <FONT
STYLE="white-space:nowrap">non-competition</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> are hereby incorporated by reference and shall remain in full force and effect pursuant to their terms to the maximum extent permitted by
applicable law, except that the Parties expressly agree to modify the Restrictive Covenant Agreement by removing the words &#147;, if I am terminated by the Company for Cause or if I resign for any reason&#148; from Section&nbsp;6.1(a) and removing
Section&nbsp;6.1(c) of the Restrictive Covenant Agreement, which deleted provisions shall be of no further force or effect upon the Effective Date (as defined below). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Executive&#146;s continued compliance with the terms of Section&nbsp;9 of the Employment
Agreement (as modified in Section&nbsp;4(a) above) (collectively, the &#147;<U>Restrictive Covenants</U>&#148;) is a material condition to receipt of the severance payments and benefits set forth in Section&nbsp;1 of this Agreement. In the event
Executive breaches any part of such Restrictive Covenants, then, in addition to any remedies and enforcement mechanisms set forth in the Employment Agreement and this Agreement, and any other remedies available to the Company (including equitable
and injunctive remedies), Executive shall forfeit any additional consideration owing and shall be obligated to promptly return to the Company (within fifteen (15)&nbsp;business days of any breach) the full gross amount of all severance payments and
benefits provided. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Severability</U>. In the event that any provision or any portion of any provision hereof or any surviving
agreement made a part hereof becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable or void, this Release shall continue in full force and effect without said provision or portion of provision. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>No Oral Modification</U>. This Release may only be amended in a writing signed by Executive and a duly authorized officer of the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Governing Law; Dispute Resolution</U>. This Release shall be subject to the provisions of Sections 9(a), 9(c) and 9(h) of the
Employment Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Effective Date</U>. Executive understands that this Release shall become effective, irrevocable, and binding
upon Executive on the day following the seventh (7th) business day from the date upon which Executive signs this Release, so long as Executive has not revoked it within the time period and in the manner specified in Section&nbsp;3 above. Executive
further understands that Executive will not be given any severance benefits under the Agreement unless this Release becomes effective pursuant to its terms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Voluntary Execution of Agreement</U>. Executive understands and agrees that Executive executed this Release voluntarily, without any
duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Executive&#146;s claims against the Company and any of the other Releasees. Executive acknowledges that: (a)&nbsp;Executive
has read this Release; (b)&nbsp;Executive has not relied upon any representations or statements made by the Company that are not specifically set forth in this Release; (c)&nbsp;Executive has been represented in the preparation, negotiation and
execution of this Release by legal counsel of Executive&#146;s own choice or has elected not to retain legal counsel; (d)&nbsp;Executive understands the terms and consequences of this Release and of the releases it contains; and (e)&nbsp;Executive
is fully aware of the legal and binding effect of this Release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Release on the respective dates set forth
below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Harlan Waksal</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>LYRA THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Maria Palasis, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title: President and Chief Executive Officer</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT C </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Restrictive Covenant Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[attached] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[intentionally
omitted] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>d309078dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 INCENTIVE AWARD PLAN </B></P></div>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PERFORMANCE STOCK OPTION GRANT NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms not specifically defined in this Performance Stock Option Grant Notice (the &#147;<B><I>Grant Notice</I></B>&#148;) have the
meanings given to them in the 2020 Incentive Award Plan<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>(as amended from time to time, the &#147;<B><I>Plan</I></B>&#148;) of Lyra Therapeutics, Inc. (the &#147;<B><I>Company</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has granted to the participant listed below (&#147;<B><I>Participant</I></B>&#148;) the stock option described in this Grant
Notice (the &#147;<B><I>Option</I></B>&#148;), subject to the terms and conditions of the Plan and the Performance Stock Option Agreement attached as <B>Exhibit A</B> (the &#147;<B><I>Agreement</I></B>&#148;), both of which are incorporated into
this Grant Notice by reference. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="98%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Participant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Maria Palasis</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Grant Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">February&nbsp;16, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise Price per Share:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$4.21</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Shares Subject to the Option:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">175,000</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Final Expiration Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">February&nbsp;15, 2032</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Conditions:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Option will vest based on the achievement of both Performance Vesting Conditions and Service Vesting Conditions, in each case, as set forth in <B>Exhibit A</B> and <B>Schedule I</B> to this Grant Notice.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Type of Option</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Incentive Stock Option</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By Participant&#146;s signature below, Participant agrees to be bound by the terms of this Grant Notice,
the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of
the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LYRA THERAPEUTICS, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>PARTICIPANT</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ C. Ann Merrifield</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maria Palasis, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">C. Ann Merrifield</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Chair of the Compensation Committee of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PERFORMANCE STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant
Notice, in the Plan. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Grant of
Option</U>. The Company has granted to Participant the Option effective as of the grant date set forth in the Grant Notice (the &#147;<B><I>Grant Date</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Incorporation of Terms of Plan</U>. The Option is subject to the terms and conditions set forth in this Agreement and the Plan, which
is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 <U>Defined Terms</U>. As used in this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B><I>Employment Agreement</I></B>&#148; means the employment agreement entered into by and between the Company and Participant,
dated April&nbsp;27, 2020, as it may be amended from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B><I>Good Reason</I></B>&#148; shall have the meaning set
forth in the Employment Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B><I>Market Capitalization</I></B>&#148; means, on a particular trading day for purposes of
each Market Capitalization Goal, an amount equal to the product of (i)&nbsp;the <FONT STYLE="white-space:nowrap">Thirty-Day</FONT> VWAP, and (ii)&nbsp;the average of the total number of outstanding Shares during such
<FONT STYLE="white-space:nowrap">Thirty-Day</FONT> VWAP period, as determined by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B><I>Market Capitalization
Goal</I></B>&#148; means, for each applicable Tranche, the Market Capitalization goal set forth next to such Tranche as shown on the attached Schedule I. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B><I>Performance Period</I></B>&#148; means the period beginning on the Grant Date and ending on the fifth (5<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) anniversary of the Grant Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B><I>Performance Vesting
Conditions</I></B>&#148; means the achievement of each Market Capitalization Goal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B><I>Service Vesting
Conditions</I></B>&#148; means the service-based vesting conditions set forth in Section&nbsp;2.1(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B><I><FONT
STYLE="white-space:nowrap">Thirty-Day</FONT> VWAP</I></B>&#148; means the volume weighted average trading price per Share measured over any rolling thirty trading day period within the Performance Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B><I>trading day</I></B>&#148; means a day on which the primary stock exchange or national market system on which the Shares trade
is open for trading. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PERIOD OF EXERCISABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Commencement of Exercisability</U>. The Option shall be divided into three (3)&nbsp;tranches (each a
&#147;<B><I>Tranche</I></B>&#148;), as shown on the attached Schedule I, and, subject to Section&nbsp;2.2 and Section&nbsp;2.3, the Option will vest and become exercisable with respect to each Tranche upon satisfaction of both (i)&nbsp;the
applicable Performance Vesting Condition and (ii)&nbsp;the applicable Service Vesting Condition, as follows: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Tranche shall satisfy the Performance Vesting Condition if and when during
the&nbsp;Performance Period&nbsp;the Company&#146;s&nbsp;Market Capitalization&nbsp;equals or exceeds the applicable&nbsp;Market Capitalization Goal,&nbsp;subject&nbsp;to Participant&#146;s remaining a Service Provider with the Company through such
time, and&nbsp;subject&nbsp;further to the Administrator&#146;s determination, approval and certification that the applicable&nbsp;Market Capitalization Goal for such Tranche has been satisfied (a &#147;<B><I>Certification</I></B>&#148;). During
the&nbsp;Performance Period, the Administrator shall periodically assess whether the Performance Vesting Conditions have been satisfied. The Administrator shall also engage in such assessment reasonably promptly upon the reasonable request of
Participant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Tranche 1 in the attached Schedule I will satisfy the Service Vesting Condition if Participant remains a Service Provider
through the first anniversary of the Grant Date. Tranche 2 in the attached Schedule I will satisfy the Service Vesting Condition if Participant remains a Service Provider through the second anniversary of the Grant Date. Tranche 3 in the attached
Schedule I will satisfy the Service Vesting Condition if Participant remains a Service Provider through the third anniversary of the Grant Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In no event may the Option become vested and exercisable with respect to more than the number of Shares subject to the Option shown on the
Grant Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Change in Control</U>. Notwithstanding anything to the contrary in this Agreement, if a Change in Control occurs
during the&nbsp;Performance Period, then, subject to Participant remaining a Service Provider through the date of the Change in Control, except as provided in Section&nbsp;2.3(a), (i) if not earlier satisfied, the Market Capitalization Goal for each
Tranche will be deemed satisfied upon the effective time of the Change in Control and (ii)&nbsp;any Tranche that has satisfied or is deemed to satisfy the Performance Vesting Condition as of the date of the Change in Control, pursuant to this
Section&nbsp;2.2, but has not yet satisfied the Service Vesting Conditions as of the date of the Change in Control shall, to the extent the Option is assumed, substituted or continued in such Change in Control, continue to be eligible to vest upon
satisfaction of the Service Vesting Conditions, subject to Section&nbsp;2.3, or to the extent the Option is not assumed, substituted or continued in such Change in Control become vested as of the immediately prior to such Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Termination. </U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In
the event of Participant&#146;s Termination of Service by the Company without Cause or due to Participant&#146;s resignation with Good Reason, in either case, within three (3)&nbsp;months preceding or twelve (12)&nbsp;months following the date of a
Change in Control, any Tranches that have satisfied the Performance Vesting Condition as of the date of such Termination of Service or that are deemed to satisfy the Performance Vesting Condition upon the Change in Control pursuant to
Section&nbsp;2.2, shall vest immediately as of the effective time of the Change in Control or, if later, upon such Termination of Service (and for the avoidance of doubt, in the event of such a Termination of Service within three (3)&nbsp;months
prior to a Change in Control, Tranches that have not satisfied the Performance Vesting Condition as of such Termination of Service will remain eligible to vest upon the occurrence of a Change in Control within three (3)&nbsp;months after such
Termination of Service and will thereafter be forfeited to the extent not vested). Unless otherwise determined by the Administrator, the vesting set forth in this Section&nbsp;2.3(a) shall be subject to Participant&#146;s execution (and <FONT
STYLE="white-space:nowrap">non-revocation)</FONT> of a general release of claims in substantially the form attached to the Employment Agreement within the time limits prescribed therein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event of Participant&#146;s Termination of Service other than as set forth in Section&nbsp;2.3(a), all then-unvested Tranches will
immediately and automatically be cancelled and forfeited without consideration therefor, except as otherwise determined by the Administrator. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Administrator shall make a final assessment reasonably promptly following the last
day of the Performance Period as to whether any Tranche satisfied the applicable Performance Vesting Condition as of the last day of the Performance Period. Any Tranche that has not become vested on or prior to the last day of the Performance Period
will immediately and automatically be cancelled and forfeited without consideration therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Duration of Exercisability</U>. Any
portion of the Option which vests and becomes exercisable will remain vested and exercisable until the Option expires. The Option will be forfeited immediately upon its expiration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 <U>Expiration of Option</U>. The Option may not be exercised to any extent by anyone after, and will expire on, the first of the following
to occur: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The final expiration date in the Grant Notice; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as the Administrator may otherwise approve or as provided in the Employment Agreement, the expiration of three (3)&nbsp;months from
the date of Participant&#146;s Termination of Service, unless Participant&#146;s Termination of Service is for Cause or by reason of Participant&#146;s death or Disability; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as the Administrator may otherwise approve, the expiration of one (1)&nbsp;year from the date of Participant&#146;s Termination of
Service by reason of Participant&#146;s death or Disability; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as the Administrator may otherwise approve, Participant&#146;s
Termination of Service for Cause. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXERCISE OF OPTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1
<U>Person Eligible to Exercise</U>. During Participant&#146;s lifetime, only Participant may exercise the Option. After Participant&#146;s death, any exercisable portion of the Option may, prior to the time the Option expires, be exercised by
Participant&#146;s Designated Beneficiary as provided in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Partial Exercise</U>. Any exercisable portion of the Option or
the entire Option, if then wholly exercisable, may be exercised, in whole or in part, according to the procedures in the Plan at any time prior to the time the Option or portion thereof expires, except that the Option may only be exercised for whole
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Tax Withholding</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company has the right and option, but not the obligation, to treat Participant&#146;s failure to provide timely payment in accordance
with the Plan of any withholding tax arising in connection with the Option as Participant&#146;s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise issuable under the Option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the Option, regardless
of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the Option. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any
tax withholding in connection with the awarding, vesting or exercise of the Option or the subsequent sale of Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure the Option to reduce or eliminate
Participant&#146;s tax liability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER PROVISIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1
<U>Adjustments</U>. Participant acknowledges that the Option is subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Notices</U>. Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in
care of the Company&#146;s Secretary at the Company&#146;s principal office or the Secretary&#146;s then-current email address or facsimile number. Any notice to be given under the terms of this Agreement to Participant must be in writing and
addressed to Participant (or, if Participant is then deceased, to the person entitled to exercise the Option) at Participant&#146;s last known mailing address, email address or facsimile number in the Company&#146;s personnel files. By a notice
given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt
requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile
transmission confirmation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Titles</U>. Titles are provided herein for convenience only and are not to serve as a basis for
interpretation or construction of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <U>Conformity to Securities Laws</U>. Participant acknowledges that the Plan, the
Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5 <U>Successors and Assigns</U>. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this
Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal
representatives, successors and assigns of the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6 <U>Limitations Applicable to Section</U><U></U><U>&nbsp;16
Persons</U>. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&nbsp;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the Option will be subject to any additional limitations
set forth in any applicable exemptive rule under Section&nbsp;16 of the Exchange Act (including any amendment to <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3)</FONT> that are requirements for the application of such exemptive rule. To the extent
Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7 <U>Entire
Agreement</U>. The Plan, the Grant Notice and this Agreement (including any exhibit&nbsp;hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with
respect to the subject matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.8 <U>Agreement Severable</U>. In the event that any provision of the Grant Notice or this
Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.9 <U>Limitation on Participant&#146;s Rights</U>. Participation in the Plan confers no
rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in
and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Option, and rights no greater than the right to
receive the Shares as a general unsecured creditor with respect to the Option, as and when exercised pursuant to the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.10
<U>Not a Contract of Employment</U>. Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the
rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided
otherwise in a written agreement between the Company or a Subsidiary and Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.11 <U>Counterparts</U>. The Grant Notice may be
executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.12 <U>Incentive Stock Options</U>. If the Option is designated as an Incentive Stock Option: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Participant acknowledges that to the extent the aggregate fair market value of shares (determined as of the time the option with respect
to the shares is granted) with respect to which stock options intended to qualify as &#147;incentive stock options&#148; under Section&nbsp;422 of the Code, including the Option, are exercisable for the first time by Participant during any calendar
year exceeds $100,000 or if for any other reason such stock options do not qualify or cease to qualify for treatment as &#147;incentive stock options&#148; under Section&nbsp;422 of the Code, such stock options (including the Option) will be treated
as <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options. Participant further acknowledges that the rule set forth in the preceding sentence will be applied by taking the Option and other stock options into account in the order in
which they were granted, as determined under Section&nbsp;422(d) of the Code. Participant acknowledges that amendments or modifications made to the Option pursuant to the Plan that would cause the Option to become a
<FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option will not materially or adversely affect Participant&#146;s rights under the Option, and that any such amendment or modification shall not require Participant&#146;s consent.
Participant also acknowledges that if the Option is exercised more than three (3)&nbsp;months after Participant&#146;s Termination of Service as an Employee, other than by reason of death or disability, the Option will be taxed as a <FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Participant will give prompt written notice to the Company of any
disposition or other transfer of any Shares acquired under this Agreement if such disposition or other transfer is made (a)&nbsp;within two (2)&nbsp;years from the Grant Date or (b)&nbsp;within one (1)&nbsp;year after the transfer of such Shares to
Participant. Such notice will specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by Participant in such disposition or other transfer. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*&nbsp;*&nbsp;*&nbsp;*&nbsp;* </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule I </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Tranche</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;Capitalization&nbsp;Goals<BR>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>175,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>d309078dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 INDUCEMENT INCENTIVE AWARD PLAN </B></P></div>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PERFORMANCE STOCK OPTION GRANT NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms not specifically defined in this Performance Stock Option Grant Notice (the &#147;<B><I>Grant Notice</I></B>&#148;) have the
meanings given to them in the 2022 Inducement Incentive Award Plan (as amended from time to time, the &#147;<B><I>Plan</I></B>&#148;) of Lyra Therapeutics, Inc. (the &#147;<B><I>Company</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has granted to the participant listed below (&#147;<B><I>Participant</I></B>&#148;) the stock option described in this Grant
Notice (the &#147;<B><I>Option</I></B>&#148;), subject to the terms and conditions of the Plan and the Performance Stock Option Agreement attached as <B>Exhibit A</B> (the &#147;<B><I>Agreement</I></B>&#148;), both of which are incorporated into
this Grant Notice by reference. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Participant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Harlan Waksal</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Grant Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">February&nbsp;16, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise Price per Share:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Shares Subject to the Option:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">520,000</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Final Expiration Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">February&nbsp;15, 2032</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Conditions:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Option will vest based on the achievement of both Performance Vesting Conditions and Service Vesting Conditions, in each case, as set forth in <B>Exhibit A</B> and <B>Schedule I</B> to this Grant Notice.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Type of Option</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By Participant&#146;s signature below, Participant agrees to be bound by the terms of this Grant Notice,
the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of
the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LYRA THERAPEUTICS, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>PARTICIPANT</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maria Palasis, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Harlan Waksal, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Maria Palasis, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PERFORMANCE STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant
Notice, in the Plan. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Grant of
Option</U>. The Company has granted to Participant the Option effective as of the grant date set forth in the Grant Notice (the &#147;<B><I>Grant Date</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Incorporation of Terms of Plan</U>. The Option is subject to the terms and conditions set forth in this Agreement and the Plan, which
is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 <U>Defined Terms</U>. As used in this Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B><I>Employment Agreement</I></B>&#148; means the employment agreement entered into by and between the Company and Participant,
dated February&nbsp;16, 2022, as it may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B><I>Good Reason</I></B>&#148; shall have the meaning
set forth in the Employment Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B><I>Market Capitalization</I></B>&#148; means, on a particular trading day for
purposes of each Market Capitalization Goal, an amount equal to the product of (i)&nbsp;the <FONT STYLE="white-space:nowrap">Thirty-Day</FONT> VWAP, and (ii)&nbsp;the average of the total number of outstanding Shares during such <FONT
STYLE="white-space:nowrap">Thirty-Day</FONT> VWAP period, as determined by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B><I>Market Capitalization
Goal</I></B>&#148; means, for each applicable Tranche, the Market Capitalization goal set forth next to such Tranche as shown on the attached Schedule I. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B><I>Performance Period</I></B>&#148; means the period beginning on the Grant Date and ending on the fifth (5<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) anniversary of the Grant Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B><I>Performance Vesting
Conditions</I></B>&#148; means the achievement of each Market Capitalization Goal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B><I>Service Vesting
Conditions</I></B>&#148; means the service-based vesting conditions set forth in Section&nbsp;2.1(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B><I><FONT
STYLE="white-space:nowrap">Thirty-Day</FONT> VWAP</I></B>&#148; means the volume weighted average trading price per Share measured over any rolling thirty trading day period within the Performance Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B><I>trading day</I></B>&#148; means a day on which the primary stock exchange or national market system on which the Shares trade
is open for trading. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PERIOD OF EXERCISABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Commencement of Exercisability</U>. The Option shall be divided into three (3)&nbsp;tranches (each a
&#147;<B><I>Tranche</I></B>&#148;), as shown on the attached Schedule I, and, subject to Section&nbsp;2.2 and Section&nbsp;2.3, the Option will vest and become exercisable with respect to each Tranche upon satisfaction of both (i)&nbsp;the
applicable Performance Vesting Condition and (ii)&nbsp;the applicable Service Vesting Condition, as follows: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Tranche shall satisfy the Performance Vesting Condition if and when during the
Performance Period the Company&#146;s Market Capitalization equals or exceeds the applicable Market Capitalization Goal, subject to Participant remaining a Service Provider with the Company through such time, and subject further to the
Administrator&#146;s determination, approval and certification that the applicable Market Capitalization Goal for such Tranche has been satisfied (a &#147;<B><I>Certification</I></B>&#148;). During the Performance Period, the Administrator shall
periodically assess whether the Performance Vesting Conditions have been satisfied. The Administrator shall also engage in such assessment reasonably promptly upon the reasonable request of Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Tranche 1 in the attached Schedule I will satisfy the Service Vesting Condition if Participant remains a Service Provider through the
first anniversary of the Grant Date. Tranche 2 in the attached Schedule I will satisfy the Service Vesting Condition if Participant remains a Service Provider through the second anniversary of the Grant Date. Tranche 3 in the attached Schedule I
will satisfy the Service Vesting Condition if Participant remains a Service Provider through the third anniversary of the Grant Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
In no event may the Option become vested and exercisable with respect to more than the number of Shares subject to the Option shown on the Grant Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Change in Control</U>. Notwithstanding anything to the contrary in this Agreement, if a Change in Control occurs during
the&nbsp;Performance Period, then, subject to Participant remaining a Service Provider through the date of the Change in Control, except as provided in Section&nbsp;2.3(a), (i) if not earlier satisfied, the Market Capitalization Goal for each
Tranche will be deemed satisfied upon the effective time of the Change in Control and (ii)&nbsp;any Tranche that has satisfied or is deemed to satisfy the Performance Vesting Condition as of the date of the Change in Control, pursuant to this
Section&nbsp;2.2, but has not yet satisfied the Service Vesting Conditions as of the date of the Change in Control shall, to the extent the Option is assumed, substituted or continued in such Change in Control, continue to be eligible to vest upon
satisfaction of the Service Vesting Conditions, subject to Section&nbsp;2.3, or to the extent the Option is not assumed, substituted or continued in such Change in Control become vested as of the immediately prior to such Change in Control.<U></U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Termination. </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In the event of Participant&#146;s Termination of Service by the Company without Cause or due to Participant&#146;s resignation with Good
Reason, in either case, within three (3)&nbsp;months preceding or twelve (12)&nbsp;months following the date of a Change in Control, any Tranches that have satisfied the Performance Vesting Condition as of the date of such Termination of Service or
that are deemed to satisfy the Performance Vesting Condition upon the Change in Control pursuant to Section&nbsp;2.2, shall vest immediately as of the effective time of the Change in Control or, if later, upon such Termination of Service (and for
the avoidance of doubt, in the event of such a Termination of Service within three (3)&nbsp;months prior to a Change in Control, Tranches that have not satisfied the Performance Vesting Condition as of such Termination of Service will remain
eligible to vest upon the occurrence of a Change in Control within three (3)&nbsp;months after such Termination of Service and will thereafter be forfeited to the extent not vested). Unless otherwise determined by the Administrator, the vesting set
forth in this Section&nbsp;2.3(a) shall be subject to Participant&#146;s execution (and <FONT STYLE="white-space:nowrap">non-revocation)</FONT> of a general release of claims in substantially the form attached to the Employment Agreement within the
time limits prescribed therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event of Participant&#146;s Termination of Service other than as set forth in
Section&nbsp;2.3(a), all then-unvested Tranches will immediately and automatically be cancelled and forfeited without consideration therefor, except as otherwise determined by the Administrator. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Administrator shall make a final assessment reasonably promptly following the last
day of the Performance Period as to whether any Tranche satisfied the applicable Performance Vesting Condition as of the last day of the Performance Period. Any Tranche that has not become vested on or prior to the last day of the Performance Period
will immediately and automatically be cancelled and forfeited without consideration therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Duration of Exercisability</U>. Any
portion of the Option which vests and becomes exercisable will remain vested and exercisable until the Option expires. The Option will be forfeited immediately upon its expiration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 <U>Expiration of Option</U>. The Option may not be exercised to any extent by anyone after, and will expire on, the first of the following
to occur: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The final expiration date in the Grant Notice; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as the Administrator may otherwise approve or as provided in the Employment Agreement, the expiration of six (6)&nbsp;months from
the date of Participant&#146;s Termination of Service, unless Participant&#146;s Termination of Service is for Cause or by reason of Participant&#146;s death or Disability; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as the Administrator may otherwise approve, the expiration of one (1)&nbsp;year from the date of Participant&#146;s Termination of
Service by reason of Participant&#146;s death or Disability; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as the Administrator may otherwise approve,
Participant&#146;s Termination of Service for Cause. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXERCISE OF OPTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1
<U>Person Eligible to Exercise</U>. During Participant&#146;s lifetime, only Participant may exercise the Option. After Participant&#146;s death, any exercisable portion of the Option may, prior to the time the Option expires, be exercised by
Participant&#146;s Designated Beneficiary as provided in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Partial Exercise</U>. Any exercisable portion of the Option or
the entire Option, if then wholly exercisable, may be exercised, in whole or in part, according to the procedures in the Plan at any time prior to the time the Option or portion thereof expires, except that the Option may only be exercised for whole
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Tax Withholding</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company has the right and option, but not the obligation, to treat Participant&#146;s failure to provide timely payment in accordance
with the Plan of any withholding tax arising in connection with the Option as Participant&#146;s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise issuable under the Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the Option,
regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the Option. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the
treatment of any tax withholding in connection with the awarding, vesting or exercise of the Option or the subsequent sale of Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure the Option to reduce or
eliminate Participant&#146;s tax liability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER PROVISIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1
<U>Adjustments</U>. Participant acknowledges that the Option is subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Notices</U>. Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in
care of the Company&#146;s Secretary at the Company&#146;s principal office or the Secretary&#146;s then-current email address or facsimile number. Any notice to be given under the terms of this Agreement to Participant must be in writing and
addressed to Participant (or, if Participant is then deceased, to the person entitled to exercise the Option) at Participant&#146;s last known mailing address, email address or facsimile number in the Company&#146;s personnel files. By a notice
given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt
requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile
transmission confirmation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Titles</U>. Titles are provided herein for convenience only and are not to serve as a basis for
interpretation or construction of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <U>Conformity to Securities Laws</U>. Participant acknowledges that the Plan, the
Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5 <U>Successors and Assigns</U>. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this
Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal
representatives, successors and assigns of the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6 <U>Limitations Applicable to Section</U><U></U><U>&nbsp;16
Persons</U>. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&nbsp;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the Option will be subject to any additional limitations
set forth in any applicable exemptive rule under Section&nbsp;16 of the Exchange Act (including any amendment to <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3)</FONT> that are requirements for the application of such exemptive rule. To the extent
Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7 <U>Entire
Agreement</U>. The Plan, the Grant Notice and this Agreement (including any exhibit&nbsp;hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with
respect to the subject matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.8 <U>Agreement Severable</U>. In the event that any provision of the Grant Notice or this
Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.9 <U>Limitation on Participant&#146;s Rights</U>. Participation in the Plan confers no
rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in
and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Option, and rights no greater than the right to
receive the Shares as a general unsecured creditor with respect to the Option, as and when exercised pursuant to the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.10
<U>Not a Contract of Employment</U>. Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the
rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided
otherwise in a written agreement between the Company or a Subsidiary and Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.11 <U>Counterparts</U>. The Grant Notice may be
executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*&nbsp;*&nbsp;*&nbsp;*&nbsp;* </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule I </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Tranche</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;Capitalization&nbsp;Goals<BR>(Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>520,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>d309078dex105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LYRA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 EMPLOYMENT INDUCEMENT AWARD PLAN </B></P></div>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURPOSE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan&#146;s purpose is to enhance the Company&#146;s ability to attract, retain and motivate persons who are expected to make
important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article&nbsp;XI. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELIGIBILITY
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Eligible Individuals are eligible to be granted Awards under the Plan, subject to the limitations described herein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADMINISTRATION AND DELEGATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Administration</U>. The Plan is administered by the Administrator. The Administrator has authority to determine which Eligible
Individuals receive Awards, grant Awards and set Award terms and conditions, subject to the conditions and limitations in the Plan. The Administrator also has the authority to take all actions and make all determinations under the Plan, to interpret
the Plan and Award Agreements and to adopt, amend and repeal Plan administrative rules, guidelines and practices as it deems advisable. The Administrator may correct defects and ambiguities, supply omissions and reconcile inconsistencies in the Plan
or any Award as it deems necessary or appropriate to administer the Plan and any Awards. The Administrator may adopt procedures from time to time that are intended to ensure that an individual is an Eligible Individual prior to the granting of any
Awards to such individual (including without limitation a requirement that each such individual certify to the Company prior to the receipt of an Award that he or she is not currently employed by the Company or a Subsidiary and, if previously so
employed, has had a bona fide period of interruption of employment, and that the grant of Awards is an inducement material to his or her agreement to enter into employment with the Company or a Subsidiary). The Administrator&#146;s determinations
under the Plan are in its sole discretion and will be final and binding on all persons having or claiming any interest in the Plan or any Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Appointment of Committees</U>. To the extent Applicable Laws permit, the Board may delegate any or all of its powers under the Plan to
one or more Committees. The Board may abolish any Committee or <FONT STYLE="white-space:nowrap">re-vest</FONT> in itself any previously delegated authority at any time. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK
AVAILABLE FOR AWARDS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Number of Shares</U>. Subject to adjustment under Article&nbsp;VIII and the terms of this
Article&nbsp;IV, Awards may be made under the Plan covering up to the Overall Share Limit. Shares issued under the Plan may consist of authorized but unissued Shares, Shares purchased on the open market or treasury Shares. </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Share Recycling</U>. If all or any part of an Award expires, lapses or is terminated,
exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, in any case, in a manner that results in the Company acquiring Shares covered by the Award at a price not greater than the price (as adjusted to
reflect any Equity Restructuring) paid by the Participant for such Shares or not issuing any Shares covered by the Award, the unused Shares covered by the Award will again be available for Award grants under the Plan. Further, Shares delivered
(either by actual delivery or attestation) to the Company by a Participant to satisfy the applicable exercise or purchase price of an Award and/or to satisfy any applicable tax withholding obligation (including Shares retained by the Company from
the Award being exercised or purchased and/or creating the tax obligation) will again be available for Award grants under the Plan. The payment of Dividend Equivalents in cash in conjunction with any outstanding Awards shall not count against the
Overall Share Limit. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTIONS AND STOCK APPRECIATION RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>General</U>. The Administrator may grant <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Options or Stock Appreciation Rights to
Eligible Individuals subject to the conditions and limitations in the Plan. The Administrator will determine the number of Shares covered by each Option and Stock Appreciation Right, the exercise price of each Option and Stock Appreciation Right and
the conditions and limitations applicable to the exercise of each Option and Stock Appreciation Right. A Stock Appreciation Right will entitle the Participant (or other person entitled to exercise the Stock Appreciation Right) to receive from the
Company upon exercise of the exercisable portion of the Stock Appreciation Right an amount determined by multiplying the excess, if any, of the Fair Market Value of one Share on the date of exercise over the exercise price per Share of the Stock
Appreciation Right by the number of Shares with respect to which the Stock Appreciation Right is exercised, subject to any limitations of the Plan or that the Administrator may impose and payable in cash, Shares valued at Fair Market Value or a
combination of the two as the Administrator may determine or provide in the Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Exercise Price</U>. The Administrator
will establish each Option&#146;s and Stock Appreciation Right&#146;s exercise price and specify the exercise price in the Award Agreement. The exercise price will not be less than 100% of the Fair Market Value on the grant date of the Option or
Stock Appreciation Right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Duration</U>. Each Option or Stock Appreciation Right will be exercisable at such times and as specified
in the Award Agreement, provided that the term of an Option or Stock Appreciation Right will not exceed ten years. Notwithstanding the foregoing and unless determined otherwise by the Company, in the event that on the last business day of the term
of an Option or Stock Appreciation Right (i)&nbsp;the exercise of the Option or Stock Appreciation Right is prohibited by Applicable Law, as determined by the Company, or (ii)&nbsp;Shares may not be purchased or sold by the applicable Participant
due to any Company insider trading policy (including blackout periods) or a <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreement undertaken in connection with an issuance of securities by the Company, the term of the Option or Stock
Appreciation Right shall be extended until the date that is thirty (30)&nbsp;days after the end of the legal prohibition, <FONT STYLE="white-space:nowrap">black-out</FONT> period or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, as
determined by the Company; provided, however, in no event shall the extension last beyond the ten year term of the applicable Option or Stock Appreciation Right. Notwithstanding the foregoing, if the Participant, prior to the end of the term of an
Option or Stock Appreciation Right, violates the <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality or other similar restrictive covenant provisions of any employment
contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company or any of its Subsidiaries, the right of the Participant and the Participant&#146;s transferees to exercise any Option or Stock
Appreciation Right issued to the Participant shall terminate immediately upon such violation, unless the Company otherwise determines. In addition, if, prior to the end of the term of an Option or Stock Appreciation Right, the Participant is given
notice by the Company or any of its Subsidiaries of the Participant&#146;s Termination of Service by the Company or any of its Subsidiaries for Cause, and the effective date of such Termination of Service is subsequent to the date of the delivery of
such notice, the right of the Participant and the Participant&#146;s transferees to exercise any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Option or Stock Appreciation Right issued to the Participant shall be suspended from the time of the delivery of such notice until the earlier of (i)&nbsp;such time as it is determined or
otherwise agreed that the Participant&#146;s service as a Service Provider will not be terminated for Cause as provided in such notice or (ii)&nbsp;the effective date of the Participant&#146;s Termination of Service by the Company or any of its
Subsidiaries for Cause (in which case the right of the Participant and the Participant&#146;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant will terminate immediately upon the effective date of such
Termination of Service). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Exercise</U>. Options and Stock Appreciation Rights may be exercised by delivering to the Company a
written notice of exercise, in a form the Administrator approves (which may be electronic), signed by the person authorized to exercise the Option or Stock Appreciation Right, together with, as applicable, payment in full (i)&nbsp;as specified in
Section&nbsp;5.5 for the number of Shares for which the Award is exercised and (ii)&nbsp;as specified in Section&nbsp;9.5 for any applicable taxes. Unless the Administrator otherwise determines, an Option or Stock Appreciation Right may not be
exercised for a fraction of a Share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Payment Upon Exercise</U>. Subject to Section&nbsp;10.9, any Company insider trading policy
(including blackout periods) and Applicable Laws, the exercise price of an Option must be paid by: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) cash, wire transfer
of immediately available funds or by check payable to the order of the Company, provided that the Company may limit the use of one of the foregoing payment forms if one or more of the payment forms below is permitted; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) if there is a public market for Shares at the time of exercise, unless the Company otherwise determines, (A)&nbsp;delivery
(including telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to pay the exercise price, or (B)&nbsp;the
Participant&#146;s delivery to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to pay the exercise price; provided that such
amount is paid to the Company at such time as may be required by the Administrator; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) to the extent permitted by the
Administrator, delivery (either by actual delivery or attestation) of Shares owned by the Participant valued at their Fair Market Value; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) to the extent permitted by the Administrator, surrendering Shares then issuable upon the Option&#146;s exercise valued at
their Fair Market Value on the exercise date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) to the extent permitted by the Administrator, delivery of a promissory
note or any other property that the Administrator determines is good and valuable consideration; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) to the extent
permitted by the Company, any combination of the above payment forms approved by the Administrator. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK; RESTRICTED STOCK UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 <U>General</U>. The Administrator may grant Restricted Stock, or the right to purchase Restricted Stock, to any Eligible Individual,
subject to the Company&#146;s right to repurchase all or part of such shares at their issue price or other stated or formula price from the Participant (or to require forfeiture of such shares) if conditions the Administrator specifies in the Award
Agreement are not satisfied before the end of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable restriction period or periods that the Administrator establishes for such Award and subject to the conditions and limitations in the Plan. In addition, subject to the conditions and
limitations in the Plan, the Administrator may grant to Eligible Individuals Restricted Stock Units, which may be subject to vesting and forfeiture conditions during the applicable restriction period or periods, as set forth in an Award Agreement.
The Administrator will determine and set forth in the Award Agreement the terms and conditions for each Restricted Stock and Restricted Stock Unit Award, subject to the conditions and limitations contained in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Restricted Stock</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Dividends</U>. Participants holding shares of Restricted Stock will be entitled to all ordinary cash dividends paid with
respect to such Shares, unless the Administrator provides otherwise in the Award Agreement. In addition, unless the Administrator provides otherwise, if any dividends or distributions are paid in Shares, or consist of a dividend or distribution to
holders of Common Stock of property other than an ordinary cash dividend, the Shares or other property will be subject to the same restrictions on transferability and forfeitability as the shares of Restricted Stock with respect to which they were
paid. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Stock Certificates</U>. The Company may require that the Participant deposit in escrow with the Company (or
its designee) any stock certificates issued in respect of shares of Restricted Stock, together with a stock power endorsed in blank. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3
<U>Restricted Stock Units.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Settlement</U>. The Administrator may provide that settlement of Restricted Stock
Units will occur upon or as soon as reasonably practicable after the Restricted Stock Units vest or will instead be deferred, on a mandatory basis or at the Participant&#146;s election, in a manner intended to comply with Section&nbsp;409A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Stockholder Rights</U>. A Participant will have no rights of a stockholder with respect to Shares subject to any
Restricted Stock Unit unless and until the Shares are delivered in settlement of the Restricted Stock Unit. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<U>Dividend Equivalents</U>. If the Administrator provides, a grant of Restricted Stock Units may provide a Participant with the right to receive Dividend Equivalents. Dividend Equivalents may be paid currently or credited to an account for the
Participant, settled in cash or Shares and subject to the same restrictions on transferability and forfeitability as the Restricted Stock Units with respect to which the Dividend Equivalents are granted and subject to other terms and conditions as
set forth in the Award Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER STOCK OR CASH BASED AWARDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other Stock or Cash Based Awards may be granted to Participants, including Awards entitling Participants to receive Shares to be delivered in
the future and including annual or other periodic or long-term cash bonus awards (whether based on specified Performance Criteria or otherwise), in each case subject to any conditions and limitations in the Plan. Such Other Stock or Cash Based
Awards will also be available as a payment form in the settlement of other Awards, as standalone payments and as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock or Cash Based Awards may be paid in Shares,
cash or other property, as the Administrator determines. Subject to the provisions of the Plan, the Administrator will determine the terms and conditions of each Other Stock or Cash Based Award, including any purchase price, performance goal (which
may be based on the Performance Criteria), transfer restrictions, and vesting conditions, which will be set forth in the applicable Award Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADJUSTMENTS FOR CHANGES IN COMMON STOCK </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND CERTAIN OTHER EVENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1 <U>Equity Restructuring</U><U>(a) </U>. In connection with any Equity Restructuring, notwithstanding anything to the contrary in this
Article&nbsp;VIII, the Administrator will equitably adjust each outstanding Award as it deems appropriate to reflect the Equity Restructuring, which may include adjusting the number and type of securities subject to each outstanding Award and/or the
Award&#146;s exercise price or grant price (if applicable), granting new Awards to Participants (subject to Section&nbsp;10.4), and making a cash payment to Participants. The adjustments provided under this Section&nbsp;8.1 will be nondiscretionary
and final and binding on the affected Participant and the Company; provided that the Administrator will determine whether an adjustment is equitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2 <U>Corporate Transactions</U>. In the event of any dividend or other distribution (whether in the form of cash, Common Stock, other
securities, or other property), reorganization, merger, consolidation, combination, amalgamation, repurchase, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of
the Company, or sale or exchange of Common Stock or other securities of the Company, Change in Control, issuance of warrants or other rights to purchase Common Stock or other securities of the Company, other similar corporate transaction or event,
other unusual or nonrecurring transaction or event affecting the Company or its financial statements or any change in any Applicable Laws or accounting principles, the Administrator, on such terms and conditions as it deems appropriate, either by
the terms of the Award or by action taken prior to the occurrence of such transaction or event (except that action to give effect to a change in Applicable Law or accounting principles may be made within a reasonable period of time after such
change) and either automatically or upon the Participant&#146;s request, is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to (x)&nbsp;prevent
dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any Award granted or issued under the Plan, (y)&nbsp;to facilitate such transaction or event or
(z)&nbsp;give effect to such changes in Applicable Laws or accounting principles: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) to provide for the cancellation of
any such Award in exchange for either an amount of cash or other property with a value equal to the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#146;s
rights under the vested portion of such Award, as applicable; provided that, if the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#146;s rights, in any
case, is equal to or less than zero, then the Award may be terminated without payment; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) to provide that such Award
shall vest and, to the extent applicable, be exercisable as to all shares covered thereby, notwithstanding anything to the contrary in the Plan or the provisions of such Award; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) to provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall
be substituted for by awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and/or applicable exercise or purchase price, in all cases,
as determined by the Administrator; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) to make adjustments in the number and type of shares of Common Stock (or
other securities or property) subject to outstanding Awards and/or with respect to which Awards may be granted under the Plan (including, but not limited to, adjustments of the limitations in Article&nbsp;IV hereof on the maximum number and kind of
shares which may be issued) and/or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding Awards; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) to replace such Award with other rights or property selected by the Administrator; and/or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) to provide that the Award will terminate and cannot vest, be exercised or become payable after the applicable event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3 <U>Administrative Stand Still</U>. In the event of any pending stock dividend, stock split, combination or exchange of shares, merger,
consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other extraordinary transaction or change affecting the Shares or the share price of Common Stock, including any Equity Restructuring or
any securities offering or other similar transaction, for administrative convenience, the Administrator may refuse to permit the exercise of any Award for up to sixty days before or after such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.4 <U>General</U>. Except as expressly provided in the Plan or the Administrator&#146;s action under the Plan, no Participant will have any
rights due to any subdivision or consolidation of Shares of any class, dividend payment, increase or decrease in the number of Shares of any class or dissolution, liquidation, merger, or consolidation of the Company or other corporation. Except as
expressly provided with respect to an Equity Restructuring under Section&nbsp;8.1 above or the Administrator&#146;s action under the Plan, no issuance by the Company of Shares of any class, or securities convertible into Shares of any class, will
affect, and no adjustment will be made regarding, the number of Shares subject to an Award or the Award&#146;s grant or exercise price. The existence of the Plan, any Award Agreements and the Awards granted hereunder will not affect or restrict in
any way the Company&#146;s right or power to make or authorize (i)&nbsp;any adjustment, recapitalization, reorganization or other change in the Company&#146;s capital structure or its business, (ii)&nbsp;any merger, consolidation dissolution or
liquidation of the Company or sale of Company assets or (iii)&nbsp;any sale or issuance of securities, including securities with rights superior to those of the Shares or securities convertible into or exchangeable for Shares. The Administrator may
treat Participants and Awards (or portions thereof) differently under this Article&nbsp;VIII. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL PROVISIONS APPLICABLE TO AWARDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1 <U>Transferability</U>. Except as the Administrator may determine or provide in an Award Agreement or otherwise, Awards may not be sold,
assigned, transferred, pledged or otherwise encumbered, either voluntarily or by operation of law, except by will or the laws of descent and distribution, or, subject to the Administrator&#146;s consent, pursuant to a domestic relations order, and,
during the life of the Participant, will be exercisable only by the Participant. References to a Participant, to the extent relevant in the context, will include references to a Participant&#146;s authorized transferee that the Administrator
specifically approves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2 <U>Documentation</U>. Each Award will be evidenced in an Award Agreement, which may be written or electronic,
as the Administrator determines. Each Award may contain terms and conditions in addition to those set forth in the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3 <U>Discretion</U>. Except as the Plan otherwise provides, each Award may be made alone
or in addition or in relation to any other Award. The terms of each Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards (or portions thereof) uniformly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4 <U>Termination of Status</U>. The Administrator will determine how the disability, death, retirement, authorized leave of absence or any
other change or purported change in a Participant&#146;s Service Provider status affects an Award and the extent to which, and the period during which, the Participant, the Participant&#146;s legal representative, conservator, guardian or Designated
Beneficiary may exercise rights under the Award, if applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5 <U>Withholding</U>. Each Participant must pay the Company, or make
provision satisfactory to the Administrator for payment of, any taxes required by law to be withheld in connection with such Participant&#146;s Awards by the date of the event creating the tax liability. The Company may deduct an amount sufficient
to satisfy such tax obligations based on the applicable statutory withholding rates (or such other rate as may be determined by the Company after considering any accounting consequences or costs) from any payment of any kind otherwise due to a
Participant. Subject to Section&nbsp;10.9 and any Company insider trading policy (including blackout periods), Participants may satisfy such tax obligations (i)&nbsp;in cash, by wire transfer of immediately available funds, by check made payable to
the order of the Company, provided that the Company may limit the use of the foregoing payment forms if one or more of the payment forms below is permitted, (ii)&nbsp;to the extent permitted by the Administrator, in whole or in part by delivery of
Shares, including Shares retained from the Award creating the tax obligation, valued at their Fair Market Value, (iii)&nbsp;if there is a public market for Shares at the time the tax obligations are satisfied, unless the Company otherwise
determines, (A)&nbsp;delivery (including telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to satisfy the
tax obligations, or (B)&nbsp;delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to satisfy the tax
withholding, provided that such amount is paid to the Company at such time as may be required by the Administrator, or (iv)&nbsp;to the extent permitted by the Company, any combination of the foregoing payment forms approved by the Administrator. If
any tax withholding obligation will be satisfied under clause (ii)&nbsp;of the immediately preceding sentence by the Company&#146;s retention of Shares from the Award creating the tax obligation and there is a public market for Shares at the time
the tax obligation is satisfied, the Company may elect to instruct any brokerage firm determined acceptable to the Company for such purpose to sell on the applicable Participant&#146;s behalf some or all of the Shares retained and to remit the
proceeds of the sale to the Company or its designee, and each Participant&#146;s acceptance of an Award under the Plan will constitute the Participant&#146;s authorization to the Company and instruction and authorization to such brokerage firm to
complete the transactions described in this sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.6 <U>Amendment of Award; Repricing</U>. The Administrator may amend, modify or
terminate any outstanding Award, including by substituting another Award of the same or a different type or changing the exercise or settlement date. The Participant&#146;s consent to such action will be required unless (i)&nbsp;the action, taking
into account any related action, does not materially and adversely affect the Participant&#146;s rights under the Award, or (ii)&nbsp;the change is permitted under Article&nbsp;VIII or pursuant to Section&nbsp;10.7. Notwithstanding the foregoing or
anything in the Plan to the contrary, the Administrator may, without the approval of the stockholders of the Company, reduce the exercise price per share of outstanding Options or Stock Appreciation Rights or cancel outstanding Options or Stock
Appreciation Rights in exchange for cash, other Awards or Options or Stock Appreciation Rights with an exercise price per share that is less than the exercise price per share of the original Options or Stock Appreciation Rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.7 <U>Conditions on Delivery of Stock</U>. The Company will not be obligated to deliver any
Shares under the Plan or remove restrictions from Shares previously delivered under the Plan until (i)&nbsp;all Award conditions have been met or removed to the Company&#146;s satisfaction, (ii)&nbsp;as determined by the Company, all other legal
matters regarding the issuance and delivery of such Shares have been satisfied, including any applicable securities laws and stock exchange or stock market rules and regulations, and (iii)&nbsp;the Participant has executed and delivered to the
Company such representations or agreements as the Administrator deems necessary or appropriate to satisfy any Applicable Laws. The Company&#146;s inability to obtain authority from any regulatory body having jurisdiction, which the Administrator
determines is necessary to the lawful issuance and sale of any securities, will relieve the Company of any liability for failing to issue or sell such Shares as to which such requisite authority has not been obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.8 <U>Acceleration</U>. The Administrator may at any time provide that any Award will become immediately vested and fully or partially
exercisable, free of some or all restrictions or conditions, or otherwise fully or partially realizable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.9 <U>Action Required Upon
Grant of Award</U>. Promptly following the grant of an Award, the Company shall, in accordance with NASDAQ Rule 5635(c), (a) issue a press release disclosing the material terms of the Award, including the recipient(s) of the Award and the number of
Shares involved and (b)&nbsp;provide written notice to the NASDAQ of the grant. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1 <U>No
Right to Employment or Other Status</U>. No person will have any claim or right to be granted an Award, and the grant of an Award will not be construed as giving a Participant the right to continued employment or any other relationship with the
Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan or any Award, except as expressly provided in an Award Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2 <U>No Rights as Stockholder; Certificates</U>. Subject to the Award Agreement, no Participant or Designated Beneficiary will have
any rights as a stockholder with respect to any Shares to be distributed under an Award until becoming the record holder of such Shares. Notwithstanding any other provision of the Plan, unless the Administrator otherwise determines or Applicable
Laws require, the Company will not be required to deliver to any Participant certificates evidencing Shares issued in connection with any Award and instead such Shares may be recorded in the books of the Company (or, as applicable, its transfer
agent or stock plan administrator). The Company may place legends on stock certificates issued under the Plan that the Administrator deems necessary or appropriate to comply with Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3 <U>Effective Date and Term of Plan</U>. Unless earlier terminated by the Board, the Plan will become effective on the date it is approved
by the Board and will remain in effect until the tenth anniversary of such date, but Awards previously granted may extend beyond that date in accordance with the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.4 <U>Stockholder Approval Not Required</U>. It is expressly intended that approval of the Company&#146;s stockholders not be required as a
condition of the effectiveness of the Plan, and the Plan&#146;s provisions shall be interpreted in a manner consistent with such intent for all purposes. Specifically, NASDAQ Rule 5635(c) generally requires stockholder approval for equity
compensation plans adopted by companies whose securities are listed on the NASDAQ Stock Market that provide for the delivery of equity securities to any employees, directors or other service providers of such companies as compensation for services.
NASDAQ Rule 5635(c)(4) provides an exemption in certain circumstances for employment inducement awards. Notwithstanding anything to the contrary herein, in accordance with NASDAQ Rule 5635(c)(4), Awards may only be granted as material inducements to
Eligible Individuals being hired or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rehired as Employees, as applicable, and must be approved by (a)&nbsp;the Board, acting through a majority of the Company&#146;s Independent Directors or (b)&nbsp;the independent Compensation
Committee of the Board. Accordingly, pursuant to NASDAQ Rule 5635(c)(4), the issuance of Awards and the Shares issuable upon exercise or vesting of such Awards pursuant to the Plan is not subject to the approval of the Company&#146;s stockholders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.5 <U>Amendment of Plan</U>. The Administrator may amend, suspend or terminate the Plan at any time; provided that no amendment, other
than an increase to the Overall Share Limit, may materially and adversely affect any Award outstanding at the time of such amendment without the affected Participant&#146;s consent. No Awards may be granted under the Plan during any suspension
period or after Plan termination. Awards outstanding at the time of any Plan suspension or termination will continue to be governed by the Plan and the Award Agreement, as in effect before such suspension or termination. The Board will obtain
stockholder approval of any Plan amendment to the extent necessary to comply with Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.6 <U>Provisions for Foreign
Participants</U>. The Administrator may modify Awards granted to Participants who are foreign nationals or employed outside the United States or establish subplans or procedures under the Plan to address differences in laws, rules, regulations or
customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.7
<U>Section</U><U></U><U>&nbsp;409A</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. The Company intends that all Awards be structured to comply
with, or be exempt from, Section&nbsp;409A, such that no adverse tax consequences, interest, or penalties under Section&nbsp;409A apply. Notwithstanding anything in the Plan or any Award Agreement to the contrary, the Administrator may, without a
Participant&#146;s consent, amend this Plan or Awards, adopt policies and procedures, or take any other actions (including amendments, policies, procedures and retroactive actions) as are necessary or appropriate to preserve the intended tax
treatment of Awards, including any such actions intended to (A)&nbsp;exempt this Plan or any Award from Section&nbsp;409A, or (B)&nbsp;comply with Section&nbsp;409A, including regulations, guidance, compliance programs and other interpretative
authority that may be issued after an Award&#146;s grant date. The Company makes no representations or warranties as to an Award&#146;s tax treatment under Section&nbsp;409A or otherwise. The Company will have no obligation under this
Section&nbsp;10.7 or otherwise to avoid the taxes, penalties or interest under Section&nbsp;409A with respect to any Award and will have no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan
are determined to constitute noncompliant &#147;nonqualified deferred compensation&#148; subject to taxes, penalties or interest under Section&nbsp;409A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Separation from Service</U>. If an Award constitutes &#147;nonqualified deferred compensation&#148; under
Section&nbsp;409A, any payment or settlement of such Award upon a termination of a Participant&#146;s Service Provider relationship will, to the extent necessary to avoid taxes under Section&nbsp;409A, be made only upon the Participant&#146;s
&#147;separation from service&#148; (within the meaning of Section&nbsp;409A), whether such &#147;separation from service&#148; occurs upon or after the termination of the Participant&#146;s Service Provider relationship. For purposes of this Plan
or any Award Agreement relating to any such payments or benefits, references to a &#147;termination,&#148; &#147;termination of employment&#148; or like terms means a &#147;separation from service.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Payments to Specified Employees</U>. Notwithstanding any contrary provision in the Plan or any Award Agreement, any
payment(s) of &#147;nonqualified deferred compensation&#148; required to be made under an Award to a &#147;specified employee&#148; (as defined under Section&nbsp;409A and as the Administrator determines) due to his or her &#147;separation from
service&#148; will, to the extent necessary to avoid taxes under Section&nbsp;409A(a)(2)(B)(i) of the Code, be delayed for the <FONT STYLE="white-space:nowrap">six-month</FONT> period </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
immediately following such &#147;separation from service&#148; (or, if earlier, until the specified employee&#146;s death) and will instead be paid (as set forth in the Award Agreement) on the
day immediately following such <FONT STYLE="white-space:nowrap">six-month</FONT> period or as soon as administratively practicable thereafter (without interest). Any payments of &#147;nonqualified deferred compensation&#148; under such Award payable
more than six months following the Participant&#146;s &#147;separation from service&#148; will be paid at the time or times the payments are otherwise scheduled to be made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.8 <U>Limitations on Liability</U>. Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, other
employee or agent of the Company or any Subsidiary will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan or any Award, and such
individual will not be personally liable with respect to the Plan because of any contract or other instrument executed in his or her capacity as an Administrator, director, officer, other employee or agent of the Company or any Subsidiary. The
Company will indemnify and hold harmless each director, officer, other employee and agent of the Company or any Subsidiary that has been or will be granted or delegated any duty or power relating to the Plan&#146;s administration or interpretation,
against any cost or expense (including attorneys&#146; fees) or liability (including any sum paid in settlement of a claim with the Administrator&#146;s approval) arising from any act or omission concerning this Plan unless arising from such
person&#146;s own fraud or bad faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.9 <U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</U>. The Company may, at the request
of any underwriter representative or otherwise, in connection with registering the offering of any Company securities under the Securities Act, prohibit Participants from, directly or indirectly, selling or otherwise transferring any Shares or other
Company securities during a period of up to one hundred eighty days following the effective date of a Company registration statement filed under the Securities Act, or such longer period as determined by the underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.10 <U>Data Privacy</U>. As a condition for receiving any Award, each Participant explicitly and unambiguously consents to the collection,
use and transfer, in electronic or other form, of personal data as described in this section by and among the Company and its Subsidiaries and affiliates exclusively for implementing, administering and managing the Participant&#146;s participation
in the Plan. The Company and its Subsidiaries and affiliates may hold certain personal information about a Participant, including the Participant&#146;s name, address and telephone number; birthdate; social security, insurance number or other
identification number; salary; nationality; job title(s); any Shares held in the Company or its Subsidiaries and affiliates; and Award details, to implement, manage and administer the Plan and Awards (the &#147;<B><I>Data</I></B>&#148;). The Company
and its Subsidiaries and affiliates may transfer the Data amongst themselves as necessary to implement, administer and manage a Participant&#146;s participation in the Plan, and the Company and its Subsidiaries and affiliates may transfer the Data
to third parties assisting the Company with Plan implementation, administration and management. These recipients may be located in the Participant&#146;s country, or elsewhere, and the Participant&#146;s country may have different data privacy laws
and protections than the recipients&#146; country. By accepting an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, to implement, administer and manage the
Participant&#146;s participation in the Plan, including any required Data transfer to a broker or other third party with whom the Company or the Participant may elect to deposit any Shares. The Data related to a Participant will be held only as long
as necessary to implement, administer, and manage the Participant&#146;s participation in the Plan. A Participant may, at any time, view the Data that the Company holds regarding such Participant, request additional information about the storage and
processing of the Data regarding such Participant, recommend any necessary corrections to the Data regarding the Participant or refuse or withdraw the consents in this Section&nbsp;10.10 in writing, without cost, by contacting the local human
resources representative. The Company may cancel Participant&#146;s ability to participate in the Plan and, in the Administrator&#146;s discretion, the Participant may forfeit any outstanding Awards if the Participant refuses or withdraws the
consents in this Section&nbsp;10.10. For more information on the consequences of refusing or withdrawing consent, Participants may contact their local human resources representative. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.11 <U>Severability</U>. If any portion of the Plan or any action taken under it is held
illegal or invalid for any reason, the illegality or invalidity will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or invalid provisions had been excluded, and the illegal or invalid action
will be null and void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.12 <U>Governing Documents</U>. If any contradiction occurs between the Plan and any Award Agreement or other
written agreement between a Participant and the Company (or any Subsidiary) that the Administrator has approved, the Plan will govern, unless it is expressly specified in such Award Agreement or other written document that a specific provision of
the Plan will not apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.13 <U>Governing Law</U>. The Plan and all Awards will be governed by and interpreted in accordance with the
laws of the State of Delaware, disregarding any state&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">choice-of-law</FONT></FONT> principles requiring the application of a jurisdiction&#146;s laws other than the State of
Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.14 <U>Claw-back Provisions</U>. All Awards (including any proceeds, gains or other economic benefit the Participant actually
or constructively receives upon receipt or exercise of any Award or the receipt or resale of any Shares underlying the Award) will be subject to any Company claw-back policy, including any claw-back policy adopted to comply with Applicable Laws
(including the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder) as set forth in such claw-back policy or the Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.15 <U>Titles and Headings</U>. The titles and headings in the Plan are for convenience of reference only and, if any conflict, the
Plan&#146;s text, rather than such titles or headings, will control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.16 <U>Conformity to Securities Laws</U>. Participant acknowledges
that the Plan is intended to conform to the extent necessary with Applicable Laws. Notwithstanding anything herein to the contrary, the Plan and all Awards will be administered only in conformance with Applicable Laws. To the extent Applicable Laws
permit, the Plan and all Award Agreements will be deemed amended as necessary to conform to Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.17 <U>Relationship to
Other Benefits</U>. No payment under the Plan will be taken into account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except as
expressly provided in writing in such other plan or an agreement thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.18 <U>Broker-Assisted Sales</U>. In the event of a
broker-assisted sale of Shares in connection with the payment of amounts owed by a Participant under or with respect to the Plan or Awards, including amounts to be paid under the final sentence of Section&nbsp;9.5: (a) any Shares to be sold through
the broker-assisted sale will be sold on the day the payment first becomes due, or as soon thereafter as practicable; (b)&nbsp;such Shares may be sold as part of a block trade with other Participants in the Plan in which all participants receive an
average price; (c)&nbsp;the applicable Participant will be responsible for all broker&#146;s fees and other costs of sale, and by accepting an Award, each Participant agrees to indemnify and hold the Company harmless from any losses, costs, damages,
or expenses relating to any such sale; (d)&nbsp;to the extent the Company or its designee receives proceeds of such sale that exceed the amount owed, the Company will pay such excess in cash to the applicable Participant as soon as reasonably
practicable; (e)&nbsp;the Company and its designees are under no obligation to arrange for such sale at any particular price; and (f)&nbsp;in the event the proceeds of such sale are insufficient to satisfy the Participant&#146;s applicable
obligation, the Participant may be required to pay immediately upon demand to the Company or its designee an amount in cash sufficient to satisfy any remaining portion of the Participant&#146;s obligation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in
the Plan, the following words and phrases will have the following meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1 &#147;<B><I>Administrator</I></B>&#148; means the Board
or a Committee to the extent that the Board&#146;s powers or authority under the Plan have been delegated to such Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.2
&#147;<B><I>Applicable Laws</I></B>&#148; means the requirements relating to the administration of equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any
stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where Awards are granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.3 &#147;<B><I>Award</I></B>&#148; means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights,
Restricted Stock, Restricted Stock Units or Other Stock or Cash Based Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.4 &#147;<B><I>Award Agreement</I></B>&#148; means a
written agreement evidencing an Award, which may be electronic, that contains such terms and conditions as the Administrator determines, consistent with and subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.5 &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.6 &#147;<B><I>Cause</I></B>&#148; means (i)&nbsp;if a Participant is a party to a written employment or consulting agreement with the
Company or any of its Subsidiaries or an Award Agreement in which the term &#147;cause&#148; is defined (a &#147;<B><I>Relevant Agreement</I></B>&#148;), &#147;Cause&#148; as defined in the Relevant Agreement, and (ii)&nbsp;if no Relevant Agreement
exists, (A)&nbsp;the Administrator&#146;s determination that the Participant failed to substantially perform the Participant&#146;s duties (other than a failure resulting from the Participant&#146;s Disability); (B) the Administrator&#146;s
determination that the Participant failed to carry out, or comply with any lawful and reasonable directive of the Board or the Participant&#146;s immediate supervisor; (C)&nbsp;the occurrence of any act or omission by the Participant that could
reasonably be expected to result in (or has resulted in) the Participant&#146;s conviction, plea of no contest, plea of nolo contendere, or imposition of unadjudicated probation for any felony or indictable offense or crime involving moral
turpitude; (D)&nbsp;the Participant&#146;s unlawful use (including being under the influence) or possession of illegal drugs on the premises of the Company or any of its Subsidiaries or while performing the Participant&#146;s duties and
responsibilities for the Company or any of its Subsidiaries; or (E)&nbsp;the Participant&#146;s commission of an act of fraud, embezzlement, misappropriation, misconduct, or breach of fiduciary duty against the Company or any of its Subsidiaries.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.7 &#147;<B><I>Change in Control</I></B>&#148; means and includes each of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) a transaction or series of transactions (other than an offering of Common Stock to the general public through a
registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i)&nbsp;and (ii) of subsection (c)&nbsp;below) whereby any &#147;person&#148; or related
&#147;group&#148; of &#147;persons&#148; (as such terms are used in Sections&nbsp;13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries
or a &#147;person&#148; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#146;s securities outstanding immediately after such acquisition; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) during any period of two consecutive years, individuals who, at the
beginning of such period, constitute the Board together with any new Director(s) (other than a Director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a)&nbsp;or
(c)) whose election by the Board or nomination for election by the Company&#146;s stockholders was approved by a vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the Directors then still in office who either were Directors at
the beginning of the <FONT STYLE="white-space:nowrap">two-year</FONT> period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or
more intermediaries) of (x)&nbsp;a merger, consolidation, reorganization, or business combination or (y)&nbsp;a sale or other disposition of all or substantially all of the Company&#146;s assets in any single transaction or series of related
transactions or (z)&nbsp;the acquisition of assets or stock of another entity, in each case other than a transaction: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)
which results in the Company&#146;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result
of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#146;s assets or otherwise succeeds to the business of the Company (the Company or such person, the
&#147;<B><I>Successor Entity</I></B>&#148;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#146;s outstanding voting securities immediately after the transaction, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power
of the Successor Entity; <U>provided</U>, <U>however</U>, that no person or group shall be treated for purposes of this clause (ii)&nbsp;as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of
the voting power held in the Company prior to the consummation of the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if a Change in Control
constitutes a payment event with respect to any Award (or portion of any Award) that provides for the deferral of compensation that is subject to Section&nbsp;409A, to the extent required to avoid the imposition of additional taxes under
Section&nbsp;409A, the transaction or event described in subsection (a), (b) or (c)&nbsp;with respect to such Award (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing of such Award if such transaction
also constitutes a &#147;change in control event,&#148; as defined in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change
in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination of whether a
Change in Control is a &#147;change in control event&#148; as defined in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> shall be consistent with such regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.8 &#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended, and
the regulations issued thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.9 &#147;<B><I>Committee</I></B>&#148; means one or more committees or subcommittees of the Board,
which may include one or more Company directors or executive officers, to the extent Applicable Laws permit. To the extent required to comply with the provisions of Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> it is intended that each member
of the Committee will be, at the time the Committee takes any action with respect to an Award that is subject to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; within
the meaning of Rule <FONT STYLE="white-space:nowrap">16b-3;</FONT> however, a Committee member&#146;s failure to qualify as a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; within the meaning of Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT> will not invalidate any Award granted by the Committee that is otherwise validly granted under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.10 &#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.11 &#147;<B><I>Company</I></B>&#148; means Lyra Therapeutics, Inc., a Delaware corporation, or any successor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.12 &#147;<B><I>Consultant</I></B>&#148; means any person, including any adviser, engaged by the Company or its parent or Subsidiary to
render services to such entity if the consultant or adviser: (i)&nbsp;renders bona fide services to the Company; (ii)&nbsp;renders services not in connection with the offer or sale of securities in a capital-raising transaction and does not directly
or indirectly promote or maintain a market for the Company&#146;s securities; and (iii)&nbsp;is a natural person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.13
&#147;<B><I>Designated Beneficiary</I></B>&#148; means the beneficiary or beneficiaries the Participant designates, in a manner the Administrator determines, to receive amounts due or exercise the Participant&#146;s rights if the Participant dies or
becomes incapacitated. Without a Participant&#146;s effective designation, &#147;Designated Beneficiary&#148; will mean the Participant&#146;s estate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.14 &#147;<B><I>Director</I></B>&#148; means a Board member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.15 &#147;<B><I>Disability</I></B>&#148; means a permanent and total disability under Section&nbsp;22(e)(3) of the Code, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.16 &#147;<B><I>Dividend Equivalents</I></B>&#148; means a right granted to a Participant under the Plan to receive the equivalent value (in
cash or Shares) of dividends paid on Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.17 &#147;<B><I>Eligible Individual</I></B>&#148; means any individual who was not
previously an Employee or Director hired as a new Employee or rehired as an Employee following a bona fide period of interruption of employment if such person is granted an Award as a material inducement to his or her entering into employment with
the Company or a Subsidiary (within the meaning of the NASDAQ Rule 5635(c)(4)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.18 &#147;<B><I>Employee</I></B>&#148; means any
employee of the Company or its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.19 &#147;<B><I>Equity Restructuring</I></B>&#148; means a nonreciprocal transaction
between the Company and its stockholders, such as a stock dividend, stock split, <FONT STYLE="white-space:nowrap">spin-off</FONT> or recapitalization through a large, nonrecurring cash dividend, that affects the number or kind of Shares (or other
Company securities) or the share price of Common Stock (or other Company securities) and causes a change in the per share value of the Common Stock underlying outstanding Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.20 &#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.21 &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of Common
Stock determined as follows: (i)&nbsp;if the Common Stock is listed on any established stock exchange, its Fair Market Value will be the closing sales price for such Common Stock as quoted on such exchange for such date, or if no sale occurred on
such date, the last day preceding such date during which a sale occurred, as reported in The Wall Street Journal or another source the Administrator deems reliable; (ii)&nbsp;if the Common Stock is not traded on a stock exchange but is quoted on a
national market or other quotation system, the closing sales price on such date, or if no sales occurred on such date, then on the last date preceding such date during which a sale occurred, as reported in The Wall Street Journal or another source
the Administrator deems reliable; or (iii)&nbsp;without an established market for the Common Stock, the Administrator will determine the Fair Market Value in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.22 &#147;<B><I>Incentive Stock Option</I></B>&#148; means an Option intended to qualify as an &#147;incentive stock option&#148; as defined
in Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.23 &#147;<B><I>Independent Director</I></B>&#148; means a Director who qualifies as
&#147;independent&#148; within the meaning of NASDAQ Rule 5635(c)(4), or any successor rule, as such rule may be amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.24 &#147;<B><I>NASDAQ Rule 5635(c)(4)</I></B>&#148; means NASDAQ Rule 5635(c)(4), or any successor rule, and all guidance and other
interpretative authority thereunder, as such rule, guidance and other authority may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.25 &#147;<B><I><FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option</I></B>&#148; means an Option not intended to qualify as an Incentive Stock Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.26 &#147;<B><I>Option</I></B>&#148; means an option to purchase Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.27 &#147;<B><I>Other Stock or Cash Based Awards</I></B>&#148; means cash awards, awards of Shares, and other awards valued wholly or
partially by referring to, or are otherwise based on, Shares or other property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.28 &#147;<B><I>Overall Share Limit</I></B>&#148; means
520,000 Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.29 &#147;<B><I>Participant</I></B>&#148; means an Eligible Individual who has been granted an Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.30 &#147;Performance Criteria&#148; mean the criteria (and adjustments) that the Administrator may select for an Award to establish
performance goals for a performance period, which may include the following: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization, and non-cash equity-based compensation expense); gross or net
sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including but not limited to gross profits, net profits, profit growth, net operation profit or economic profit), profit return
ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital);
return on assets; return on capital or invested capital; cost of capital; return on stockholders&#146; equity; total stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or
loss per share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives
relating to research, development, regulatory, commercial, or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer
service; employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios (including those measuring liquidity,
activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand;<SUP STYLE="font-size:85%; vertical-align:top">
</SUP></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acquisition activity; investment sourcing activity; and marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such
performance goals also may be based solely by reference to the Company&#146;s performance or the performance of a Subsidiary, division, business segment or business unit of the Company or a Subsidiary, or based upon performance relative to
performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies. The Committee may provide for exclusion of the impact of an event or occurrence which the Committee determines
should appropriately be excluded, including (a)&nbsp;restructurings, discontinued operations, extraordinary items, and other unusual, infrequently occurring or <FONT STYLE="white-space:nowrap">non-recurring</FONT> charges or events, (b)&nbsp;asset
write-downs, (c)&nbsp;litigation or claim judgments or settlements, (d)&nbsp;acquisitions or divestitures, (e)&nbsp;reorganization or change in the corporate structure or capital structure of the Company, (f)&nbsp;an event either not directly
related to the operations of the Company, Subsidiary, division, business segment or business unit or not within the reasonable control of management, (g)&nbsp;foreign exchange gains and losses, (h)&nbsp;a change in the fiscal year of the Company,
(i)&nbsp;the refinancing or repurchase of bank loans or debt securities, (j)&nbsp;unbudgeted capital expenditures, (k)&nbsp;the issuance or repurchase of equity securities and other changes in the number of outstanding shares, (l)&nbsp;conversion of
some or all of convertible securities to Common Stock, (m)&nbsp;any business interruption event, (n)&nbsp;the cumulative effects of tax or accounting changes in accordance with U.S. generally accepted accounting principles, or (o)&nbsp;the effect of
changes in other laws or regulatory rules affecting reported results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.31 &#147;<B><I>Plan</I></B>&#148; means this 2022 Employment
Inducement Award Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.32 &#147;<B><I>Restricted Stock</I></B>&#148; means Shares awarded to a Participant under Article&nbsp;VI
subject to certain vesting conditions and other restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.33 &#147;<B><I>Restricted Stock Unit</I></B>&#148; means an unfunded,
unsecured right to receive, on the applicable settlement date, one Share or an amount in cash or other consideration determined by the Administrator to be of equal value as of such settlement date, subject to certain vesting conditions and other
restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.34 &#147;<B><I>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#148; means Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.35
&#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148; means Section&nbsp;409A of the Code and all regulations, guidance, compliance programs and other interpretative authority thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.36 &#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.37 &#147;<B><I>Service Provider</I></B>&#148; means an Employee, Consultant or Director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.38 &#147;<B><I>Shares</I></B>&#148; means shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.39 &#147;<B><I>Stock Appreciation Right</I></B>&#148; means a stock appreciation right granted under Article&nbsp;V. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.40 &#147;<B><I>Subsidiary</I></B>&#148; means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of
entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of
all classes of securities or interests in one of the other entities in such chain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.41 &#147;<B><I>Termination of Service</I></B>&#148;
means the date the Participant ceases to be a Service Provider. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*&nbsp;*&nbsp;*&nbsp;*&nbsp;* </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>lyra-20220216.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 2/19/2022 1:54:01 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:lyra="http://lyratherapeutics.com/20220216"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://lyratherapeutics.com/20220216"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyra-20220216_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lyra-20220216_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>lyra-20220216_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 2/19/2022 1:54:01 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>lyra-20220216_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 2/19/2022 1:54:02 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="lyra-20220216.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140443006510248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 16, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001327273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 16,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LYRA THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-1700838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">480 Arsenal Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">393-4600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LYRA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>d309078d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lyra-20220216.xsd" xlink:type="simple"/>
    <context id="duration_2022-02-16_to_2022-02-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001327273</identifier>
        </entity>
        <period>
            <startDate>2022-02-16</startDate>
            <endDate>2022-02-16</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2022-02-16_to_2022-02-16">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-02-16_to_2022-02-16"
      id="Hidden_dei_EntityCentralIndexKey">0001327273</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-02-16_to_2022-02-16">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-02-16_to_2022-02-16">2022-02-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-02-16_to_2022-02-16">LYRA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-02-16_to_2022-02-16">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-02-16_to_2022-02-16">001-39273</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-02-16_to_2022-02-16">84-1700838</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-02-16_to_2022-02-16">480 Arsenal Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-02-16_to_2022-02-16">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-02-16_to_2022-02-16">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-02-16_to_2022-02-16">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-02-16_to_2022-02-16">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-02-16_to_2022-02-16">393-4600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-02-16_to_2022-02-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-02-16_to_2022-02-16">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-02-16_to_2022-02-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-02-16_to_2022-02-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-02-16_to_2022-02-16">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-02-16_to_2022-02-16">LYRA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-02-16_to_2022-02-16">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-02-16_to_2022-02-16">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2022-02-16_to_2022-02-16">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MIR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%
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M>FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X<L-03&IAJ
MO<NF>3[+O,&@EXN1:T/9=1,92L88!.R '<(Y_<Z[5ITPX1X=\G>A^[<#K3P&
M]'@!6^A<JU3'\TLDO,3 QFU+BLX5>C(,=D",Y1]XVXG\-/O4(VSV'T:$%'J6
M"V&%E+C?Z/F-:#R!+ ]=R_$)'0.M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQ
MJK"$52Q;#X&'' E<)S"D&IND53 >"CVN*!.L>@PL(:EU&*ADMW,JI]=V<,TB
M]RI#FJ,,:&T'X:-:"Q4&L&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-
MCQ^W_ %02P,$%     @ ,8E25"0>FZ*M    ^ $  !H   !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%
MK@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J
M%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I
M2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC
M":[?#'!X=/X!4$L#!!0    ( #&)4E1ED'F2&0$  ,\#   3    6T-O;G1E
M;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:
MTMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)
M_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*
M&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7H
MK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*
M30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D<WC_0QI-^2!8ECFS_A[
MQA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ ,8E25 =!36*!
M    L0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"
M% ,4    "  QB5)4G)[KT>X    K @  $0              @ &O    9&]C
M4')O<',O8V]R92YX;6Q02P$"% ,4    "  QB5)4F5R<(Q &  "<)P  $P
M            @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M #&)4E2\=@JB4@0  -H0   8              " @0T(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    "  QB5)4GZ ;\+$"  #B#   #0
M            @ &5#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( #&)4E27
MBKL<P    !,"   +              "  7$/  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( #&)4E0<.&7J/P$  #P"   /              "  5H0  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    "  QB5)4)!Z;HJT   #X 0  &@
M        @ '&$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    "  QB5)499!YDAD!  #/ P  $P              @ &K$@  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #U$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>118</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d309078d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d309078d8k.htm">d309078d8k.htm</File>
    <File>d309078dex101.htm</File>
    <File>d309078dex102.htm</File>
    <File>d309078dex103.htm</File>
    <File>d309078dex104.htm</File>
    <File>d309078dex105.htm</File>
    <File>lyra-20220216.xsd</File>
    <File>lyra-20220216_lab.xml</File>
    <File>lyra-20220216_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d309078d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d309078d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lyra-20220216_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lyra-20220216_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lyra-20220216.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 118,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "lyra",
   "nsuri": "http://lyratherapeutics.com/20220216",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d309078d8k.htm",
      "contextRef": "duration_2022-02-16_to_2022-02-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d309078d8k.htm",
      "contextRef": "duration_2022-02-16_to_2022-02-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lyratherapeutics.com//20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-22-046719-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-046719-xbrl.zip
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MNPW\W"<T"CWSC>!W$_T5#N>;P5!H-B9,O@55[<=#A)[?3SV.O##TIO*;D2<
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MO[@EU^=7E]>WKR]OKB(11-0-2>B1&V8AQ2F$=7K$$Z2SNV5OOSZ4WIB (X@
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MVZQ/[ST@D)41UY%;EYV7I(B)9*BI+^F(Y-8"- $0ILWA/.\N,(:5Q!JZEB=
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M1L+,A0A9=Z$X&TZ%XK%(C'0U2!^Z]1KCK"U\/N=*,#=2<:2XD5%8+E5--!'
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M%MAY>'>;AFEF*]OF*PHW!I?9.1#X-;XE!UT,+GP!E)K3!N7F!/_%)S""<>Q
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M/LKR_;1[;]@[)ODZ%W3WADZPX2#R@KE$)TD#(BVV'GE/%RD=J&:<^%2O(.W
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M[);HK"@Y)\O4C1.3G-7)!+2Z#/1;VL2*M(F[-SIMXEC2H9UB<#/*>)Z6?>F
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MKU]&72:R;BRG#6K1NJ52M"-L_0\'SR5?0_/GGG0K"F_1R.)DB+Q;(W^(*:;
MI'6S(CS2D^:$B0!HV\HA;ZEZF)570 )3^\A/K&4_2D[+<_0E([\8L?L@"[/!
ML!K*T[W4]B#@4^^+(E=!1QVD@J*L$=?1-*LGE>% #N> T._[=ECJAJ4R%J99
M3D A7;4Y/;XJBN N&K=U_=,GJ(/:Y8YQH(U&E6O!.3FK1Q@E8_&,-('\QK+6
M)K.7EC%-2)NN%&O7] $<:\4< WJ*U6U[58AQ]^ZDKC'V!RL!;@$"6[$T$09R
M" XFR6 15V<ZK*+,X)JC8S&N^\<<CSA%:-61+(E'4)Z(XA")J]-LJ@PVG5W
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M@Q!(#>A#3K8B-*->[$*0D?,%TC6&+F=1D%U"<ZH89WL'HT+(CEQ9LC!C;@!
MOBL]ADLPKW6D$<C<A1HERMF 1"A0*-N(63"N\PM;'7Q1$JX'N4C/LC+G>'D(
M$ZR*D7Q"9@ZZ3".$*G)4_/#?[SUP("'M&,9)7IHT;TX=-8*VL\U*'.;><2(T
M%O2@^[A)/_1E_,.:@5A;6[;D^DM$$!+X.,V:A$[N\)@%4%IN>X!W8'\9L)J8
MGIDK1&AXPA@<7'F'VM<Q*'4%^!OAM*>\58[!Q)QB19Q>QQ*\WAWP(;LT6_/
M]@,MGV**M'[[WNU/XI']2^GGE5V>CF$R^)!=ZEUN_IF8*^^84Q3=GA&P)]R6
MM)HR1M8,?LK=K?PT1?K:/5,JDU^MPK,7D&S1N'C+0Q6(/PNJAQE!.PYR<W:
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MVK=9.KM=@G_#@<_T$=L,04E:26Q@U/(N/I*WCWRSF'19E1B1Q*PNE:?1$%*
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MV3,3\ !W:C5.>.12"LDZ2J7C[;1LQ\V(()).O8?=M0374 ?, 1U^D12=8F(
M@>!OIL+RO#!5?9HM;-,11HNA9N_PTTI@#P(2&]D?^M8M/3D]+N",MVE>$#H5
M3:3;\TZ..Z.2<K]#.E+*"8$3;L(7)JH'XFJ41!Q# A;/Z/@#<7/5W.'GU[^-
MR%5W^.+UV\,196B$W4-EFS=UDP\RAL,0LFNJU2L0I!5'G,[5_V/N)%YP('M%
MN(8]U,+L+]"<!R$ 0*!)5W";J&9+Y>2FCP2"/^G='"Y'B )7-@85\Q$5;(-?
MC&T-PR<"U7X2%>SM<)*W/>*@6=E3.>)]V[5>?]BMF*/5, H19[(%&5$6VKN7
MFFRBW0IR2OYU;VN\_3O\=[+]^WJBL@DI*@,W5+U&@A3I,H0:AT8HH E3$1F(
M_;;J151D;?,JXFQ;BGSF&$Q=2D;\JE>R:AR\<\W:-#VQF@FK=?C8<28Z@:@V
M*UMGK;ZV=Q%:>NU$U%+D<JQN!-_83O#'^O2IY? %F<F%3U]E *K\= U6\6-:
MP3U)7AE29B4%!U5N2JK!":/!T]:^%5T?!H2*?FU'%UMGH;ETNC!-:SCHF\65
MU\#>H9MOK19$E70R:4=3D5QJ4)F";+\^8-9(O#'!.L2 6+RX^'\M2",VT9"*
MM05Q0G=S%@1(OB?G<6YW*,='2HJ#!ED9EM5H#-*_ TV(&S,Z0:]4/M$F&L).
MI:1+L:#1KJ \:7+)PU)Y7&H7Q0H+%L'B-PBA6J0G]".;QH\JZ@E7PF0%:B_T
MG$7-X:2YRM@1-, J_]#-=>0:\6+?7U1XT2J/?Y]141K^JZE:4)4,S5>JW4;!
M7HS0Q)M2_5Q9"=N:R%\6*MC#TI -5?>H/!;XRU.8";4=C>6](O%B;. V,ZYO
MZ?ZR4)8].>-N5ZC, 8A E%QCT;)"53ZK+/FR0,YP?_BR@,V.Z<&$<X(OX4T_
M<=Q*UMVY#YC,N_Y"6+G/%(3,T&K-M3Q@K0M4X4<>K;BVP&8(FX' /MS$8Z1,
M!MM&L*2,2 ('QM,L:Z[$Y)(1>%Q*[[@K@#.EK/4$E-$V<(C^LE'Q.?87I,V?
MR-WUP%S$TAB+V;5L?)]APJ9K!\WW'#86TX\*1A"@?R+QT8X9P15P?X[ZK#1$
M%2!@'07)*/) V65B4[D2?53-A-1A^G3*$[[7TW2>NE0H,@'+B73J:A=2B,8"
M3G>2GE+6J,H[ITL0ZHS*%.PBZ3WZ:M,J#V[_V?,J/SKIYN''-.3I<0GHJX4L
M6%/S.C< >0"H8@C9D+2#1$NZUW]S<>$8N@ELP4'D+I(6H_ZMG>2>2ZHSE]_-
M,?F9UVWG*-[/T1HW ?#*R2E=97Q( (GD,\OE2$ISQGI33MY[T YQ6=@DZ]AC
M$9V %N=K^8;BW-P18U:E[10UC*P.LRE!+ZALYX59-FTGY*=CSNZ_P;^[U?9<
M_$0U]RC^O=N%WF9_C\N7*BF+;(+/['^J!7OY@Y_T7J,9H9B5Q0EHDP2.1M(M
M=&WN!V0,8O0L*W-'TXL61. $9 [\=[E/8U29_?4^B(L*]  :!B\<1@KD&[_!
MUDTT8A19VPN+1 J! 4S#7XL+&?ZM0 U(64!,XZE)<W8NKAR,_1"@K"T=9/E^
M4I@38'+"(QB_@HL!,D:%="[?4CZGRDP8>Y^/?/4(/92W]G6PW;:Q!'$E[49#
M3<5J8P:^@(5,$)0&-@1DQ#[0'6V"*UY<"" FS')J@#CD[3D8C[#F&O1@($H_
MFPD,X3JG(TY@!6>*<)YMCKD8I+[ )PAR9,&Z%E5VEN+1S](<"Z\(J*HLY,@)
MQ[FJ'5PL;)KM,#5V?I.K9H+3E7<A(.TN'!&> /6 RA:P/_@1J8]=C[;4"8E+
MF_*6DE^/CAR' [,B3]ZR]_=@0K2\]_#!O?TUWS[<VQ<5[I1W4$*6]OOO[_+W
M%GU/FF,_MQN.O,D/MLL_/D2,<71GX5?\T0NDGU?I&);Z#FU*PM0,OWT&JA\8
M4V\-51R#F'!?'YR 7'T>\(#$A9W8#>%6^ST_\AK-M^2WLGJ/FK'XS3 ^U8A?
MPPWN@E=O"8>5ACLJ0#<WZ -!_KM4VR&;R0,G!],_P*93H5VX45R9BJW!G)M;
MK9-,'/SM3U*QQXX(]XMW:35.X8[=?OTA-_1BJ@"^L[M[AW\0=L:CC5/[8)%J
M:6\Q)>C'G5<[R60GV;N_]W2$SG#<H#WT/AC0-<R_R>70-W),+L%@=^Q0,N#1
MT4M:U-[>7M]83 _]8SV\ZZ>U>X>WQGXY'-S9N^>^/GK6-S;3% <8IRWZBWH6
M?^_AI=;^AIE//(R>S-Y3CXL7/OP3UKH62#7N:/4@>BJ[]Y]?@\PV%^-3Y#\2
MY:+42H?K?T/L]\JG/^N=?A3,\S4KA,Z84K_T$]6HW>OYH1JO_HJ5CBM?Z<FV
MUSFE9G:9Y&"&CPAT>20F-)?6<H%RSS9HD$^%J+ A-'.NX?DH-D/M2APN'E>4
M:B@+(1E!@ZVMUS7NK\.(UU0=&05[KEYBGUZ$E,BC=H[[3&5-9<O<ACYQ?O1>
M*K,Q/"OCZ1^UKV@/Z[^<V[SV>"07L5MT%_2NV=+'W5+;1"OYC3PPK])SE25Q
MI22>K>1%SB'+UF&$-_[U%L<>W/Y6.O616_FD-S*2,&Z2)("%>5Z(S1S#F_,M
MM>"T@D:+;EP"K24S"/-+AH/4MW8[821"GV7AP#BM[U6^F0HPN0WM3$OQ'MLG
MA<(Y?2HM)%IEGV;V*+WUN$/RQLR6=? $J$E[.%@GWHDU*<>!]'05QC4<2 \/
M[D&-O )!S]&.6SJ?_G)5X#&$\J/-)MQLM([;_"1=49M_9^^%Y9?OO-?CT")&
M. 7\[CV<0O#H#[L/W*,=[3D1Y7D4-I$&!ER#]33.L?T6-AAT=D$X_SXW2[A;
M'I6FBPIA\=3)%O?9<*K]@@4@6'>,,VR8F4J(P+==HP8K8#$V L8NWTLHCE5N
M91F\7B QM*B8$E26^.6C?2%<W%%WV5&;P7')C=$\A5CZL/B JGF> J#'=WD8
M=A*:*M'*ZUZCWG2P&4.6:RMPR]%=T&HRBE_(EI)OUD9<Y2+:OIMI52MY3 Y?
M;'\+RR-L(XQ0S\N",QNEO4%?HA?^CXV&.)4M111G!MVR<T<GD=.@MD=:\+6%
MTD%CJ$"OA2N7!X48N2^@PW ,\WK@2MN6CWW.1O=^R:[*"@0;]Q0F]K9-]PP=
MJI9>3ZJR780AT4YZT8I4#QFNH!H<HH;7\R(;MV"X8T\4] E@V"T3+Y_G!C_<
MIU;3T@)2+X,"8W8RAG'36%63A#7)7[8H6"J!KR^^J4E3+\KV:O#;BVF7UJ.@
M-Z/'#1W[GY6#>566)-SNLPRN<3]R%[F.K/!286R;3Z'B\]-5#*<? %9X7!13
MC82=[7VX2N@A=7N/:T_:2XS7LB[?Y.,@ 3XI:^,N96UXL FO14N[2MD6V<.#
MYX<'<4:'QG;@!GJK02%@9[$1IFW7SIOI>N)*DF</C5C0(?*;)1=UF^GV&3)Q
M21BP2%<655>Z<_HYT51Q'7:J9V7>%@TUH5NS]$"%ZQ_741+U^B.@LC#!55\7
M:EQ4<4L1MP.PE 0;'RK,NW7!X\N=57-JHLS$$WBPD%3>E5NE4(&$57%R+Z;=
MICDCV446(EJ@M<MK$WXVU;.UE^\R%(9F)T&I(OY\K1J:N*[H\/M'R58J>(<:
M[HV@CG#Q:,E+\UEGM'FP1TD+I;&TJ;\U[HR)L[D VN._FG-8__(V2&.;-;IU
M9V_[]W^AWK^\/2-DP7OWMW]'B,7:8OW:;N;NO,+"D34PL*3.+3K>BH[X]X!P
M/0UL.,4-$4D%A)'TQ+,,F(L>=#@(@#0II7%*"1&ES3,!4L[8(Y?-W5^L)7MH
M;[_-D]YMQE1 4)Z^ER\U*&6];B]\DF^\&[R>\KT)/^Z3E; XY=X0D'?42;GS
M02@G80E3A[;9J?2Q^^3J'"1MQ%UXGV%L-YYP:1!>$T-VU&K0R/AQ;RRWAHIZ
M^0A(CI'FEI&R.,'Y&&F-A=D YCUQPV1JHCBGBBY:[Q(UYG ]!CW?"/D80I>)
M< 6=(ILC FTB:''"31B-D[444Z2Y;51(/A/6GTO29WUCT*!=M-+:QTMM\U#*
M+679XE:L9:'"[9JV*FBBD1L+DT*YMUQ:<)'61G_DI6Z\ WGVG:\)"47W3+*9
M8!M8HT 4:8F&T1MIS(<437VY;:JS?3/L9$D0=-)QEMB-Y8"NB*63<_H)""Q_
M'D"R'JP&^?+^6K2R>SLW$*4LJ%+S"<R^Q\;U0I-A#M0*>+*N?D8]]MQ:)BX9
M.W7=9($=-;>#U"25,MRIO]Q0O]<#DJF=VMV<5?4N'=RY4*RCK1U?(2?X19Z1
MEG]M953I2M!,4'E\1A?1:W!4,O>Y:N[2,T+C>6*3E=S3E>-VL*&20\S<W76E
M2WPKKDU-NR)[/JM\ORIVAO8W0H'7@>(>F)2N48*C+ZLU26Z-ZS*"/76QX=YR
M94F *D*@=<W+,YLNBIV,;8TU <@?)>G<91[Y9F/:Q?2,\VTK_GE%C2Z<+P>8
M6&W;,2?=1C$/=O8XM7#JYA%A[^(O?(G'^N5(F1;"=U.K&.6;=.YL&*@HG?;O
MW&QR8*U%'S]T*A+U&UA9Z?Q51E3N?8NH?"Z9,-[N,E?O$NQKY.-<7P&9/^SZ
M;G2K@BW=1K-3NDA7")6V[0T5G2NDJ\)/2+W)Y-5DZZ2W5MWF.LM ?H58VMWV
M?J&RK+/5V?M% G;I>@.2;=B[%EIO,>IQ&/C*7M7.CW9V;M 8S.KY14$/V&H-
M849=M08Q%?\NVZ@U5NI5")K2;_$W7%X7= 7F8;:U*LY\#&8Y,QG7%"C Y*CJ
MT_F7//-CL<_A P?BSL9'9X[B"9AE8!VB];MWO]?\%2<N']4VI\&@,#RI2LSX
M=&#O.(6-!94VU'/E%6;W56TIAPFD,:HVXUS'@*@/<-"7)/R>"PI=***MSC(6
M<JDC*.Y3P^0M/Q\;S*>SO7^G8$.GTDK;=BDF[0F5'QSAC[;*ZJG-CJUTPV7I
MEF;[8H;-,#&%J<QLW[7056"9V&KEQNJ9-78P"'9$[8;[_*, ZS_I2!_0D?Y<
M)J_1*/^)N*>MGN9R8+5H=(92WRR,>'-XA,.$UK6'6DTG.0>O?3)M0T^ U-E%
MCIF/ZC7T2>O_GM;_(X4<<06O,./]N60WO74=P'LVPW=5#\N >]O.U<E#D#\C
M^.^$%;F'F"=D736K0Q%7N!,_T$Z$*MVZ2(/WL<<[0FFNSGT&DJ9BCQDUXR8)
MF%% 5:"C.ZVLNEULR+6(;<.^QZYA8;N;H T/#1@G0O65<]7<01PC=J%_AD-,
MZ'2<HJ-)=74+W#&%JR>6*CW?VJE3?<UJQXYVO/<YUB-GD2X\Y@@ ,4<G'#J-
M*(V2O^*'"X['\DOOV-26%S6(0JWKZGG00Z*\7VU\Q^X!\\8 ?>>BH1__JQ#C
MV&Z%\KSYLAR*@$U;JL&@D/F4&/LL;\F@%>)D!:M2Y:L]T7IX6<6Q;AG?2WS?
M;E3%WK@\NJLC2^[@1A0;T:E<R>3.*A_,JMC+<.#0XB\44I% ;*;#"#WP[Y0,
MP"I,'P"\:SJ"PP4^XV[*U:;H X6<W!1\N3]\8(/P(ZP=*9O,I=@,!ZMC#S!5
M1L"?^!!";U7SY+3,V#RF*$#.M:]2W%M1;#L<244?5G'6**F!._1,+%!.Y!87
M$G!EQUEC@?3K*!BACKN+^8]C\#P5B[9J3/3>CP*W^338Q5[8_-^_8O_"_6_^
MA>L#NW<H&85U0]M*-6IRY/D/FEU :5\FL')!''L^E.L LK_WJ4CV]S8]KQ_Z
MM#<]N#;,_$_!";^F1S\76/?%H?P_UV^N%@$>C:#I(_C"MDC^Z_P7Q=(O7Q]I
M*QZ=@Y5X^]1@7M>CO9W=36P:^?@&"/>/TA4^$8-]70^'O_S]_.K(\]I;JGR=
MY_R-#W]MA/X%*[:>+O^:E&#IX2;,XFK^RY1_F88GEZ>FR\YI78>B+]N:Y;(S
MO5P/HOX>+U^G;^7!-]_*E^C^\NPZVW)L2-*ZCEG]*VT:3+V8=EIW?O$W*QBF
M?#D<E)P3MZX7#6S0Z^?_A ]?'O_TZLG_!U!+ P04    "  QB5)4@R8;AMT=
M   YF   $0   &0S,#DP-SAD97@Q,#,N:'1M[5U;<]LXLGY7E?X#RK.[Y9R2
M'5]R&\=QE1QK$M<ZMH_M9';.&T1"%C84J>7%CO;7G[X )$!2LIPXUF1F]F$G
MIDBPT=WH_OH"</_]U8>3@_WW@_[10;>S?W5\=3(X&/QK8WMK<W?_*?\)UY^:
M&\3^X=G1;^+PW=NSD[.+-VN_OC^^&JP=B&X';GJKXERE!_M'QY_$Y=5O)X,W
M:[<ZS,=[KS:?ZWA-R$A?QV_6(C7*UVBL<WO;1*;7.M[(D^G>UC1_+<S?PR3/
MDPE?&B5QOI'I_ZJ][>KOD9SH:+9WI2<J$Z?J5EPD$PEOZI\<OSM]LY;JZS&\
M:O_P8/!EK(<Z%S@ML?_T\&#_Z3G.JZ3 &?X5#%\CJ$'/VL$_XF$V?8W#[(?Z
M1F3Y+%(XD2\;/.?MK:V_V^=PQGOPIYT7T847ADD:JG0O2R(=BNWIE]=#&7R^
M3I,B#C>")$K2O=>OIS(,=7Q-M.P +?9O0\SNE)AY+UZZ0WXU<P.2-G'WY+>+
MOKAZ/[CHGP\^7AV_O>R)X].WFZV,O@=YWRI^A\*=K9TMI&EP>G7\:2#ZO_8O
MCL3Y2?^TI''_*8AQ'J4[SQY0*QVRS@<7OYQ=?.@#8?#6L[?_%&?G5\=GI^+=
M1?_T2IR> 3,'=[%Q>V<.<;GZDF_H.(3W[3W[^_V(/7@KISJ'%?M?%<) Z203
M<9*+;*H"/=*!C**9"-5(Q_"SCD4^UIDX5^DH2>'I0(G+/ D^B[-IKI-8O$ME
MG(O3)-?PRWH^5N(?/VT_>_D:.+!_?.#^NO_T^ "GB[^_>OU$C.6-@L%5MS-1
M,@:ER,2UOE'PP@0O3_C=2K!\8V0M_"SZMS(-Q7DDX_W+CRUK_-5S8,>-2G.<
MR0;9I3U@)1BR_:?PP,&ZS(2<*&!=*$9I,A$YL(?>"?_MB?H,Z$4URI.1.)FE
M4ER-52JGJH!793TD<;/)@;?)9"KC66T(7#^/+'0@5AAB@/7 :Q0-*@!Q&Q8F
M<DQ/45Z1SO"7H8J26['N<:.ZJ\X4'"0CS4A8,T*5!:D>.DI$VM#MS%,6UJC:
MN#V1%<-_JR"WA++"RC@401*'&A_)4"+X&PJ+?J(_YJEL_SI5"C0@%S+/93 &
M"H$?CB?IX_N;])7/-4@$(8V1AMNQ#L9"I@JF'"3I-$EE3O//DVZG8H%=+L.9
M2-5(I0I(9(T0K5YKY[Y>"[VT[R<% H#^X<E O!V<G%R>]]\>G[Y[L[:U1G^?
M]X^.[-^_'A]=O7^S]O.KOZ^)P[.+H\$%7394\94-@ @G_?/+P9[]QT+EJVLJ
M.C7 "$C2Q8'YQY%]\0Z\&+A[=53]\LG,A6=;DKAM;_0'>%E>A_^[<%YEYS"5
MUVICF"KY&193ID.U)V\2<-+WG$.-.+(Q:/>K);+'UKVBL#81(S(KN.9]-.8'
MF6HISF4D,YU5\_+GY!#GT/9^</SN_=6;M5<^HZK+ N0'R@"OVG%Y]IC\XA5Q
M! OE8=CUBQJFA4QG?-OVBQXZD)T_'M\&7U0:Z SL7(JV9*I2<3D&T_,P7/S;
ML\V=[3\>TXA#F;CT70K[A8=AW/;+Y[VMK:T_'NM^T;&,Q.#+5(-30S?ZW9;L
M<URRNW_ )?M)93G@7(!A%K@\#/^N2AT6MSJ* /UFN1C*#*!'PA@:4(Y6-PQZ
M *<07G'Q49,R@E&7*KW1K3_W$-0I&%8$\)X> JA,Y<"(%$:&GQIH"H?#!8AP
MJXB4.*:KM !KL&CSCR?XJ]E4(=\MPGT F5<!D8MM7=@#_T' !W\"'#QHS\A\
MGU#C<"8<%(0H^<5KT ^(Q&1> #BFP*+GWB,D8NL,]6$(OV.2!-%QA?<)X-<4
MI8>8N@;Z2XR^Z0V/ 4^J;K2Z56$9*?2:0S;',5&H3@6R.U7YK$>CC25$#3'$
M.@#R\R+6^0R)3X:Y-&&K#&GI .$!3"=3D9BF.DGQ+O5%!04MJ'8"1@6&X, #
ME68Y7(#%&.'CR8W.3+A337VI6=2X 2$'<+?BN0P"-<UQ$0]!YD!8#X.K("HR
M5# BB:P_DA&JP%*18F2CTBEP17IQ6#^<Z!B"2/ 4<%,Q35! ,_&? NT(&9<4
MQH#YTQP7"B1):S-!Q7ZH0.G>41%F_KY?6%3/(BV(DIY_8Y#T[%NCK&?/5Q9E
M509]=U&*\D',+ 9T_0L8]!A>>%4.>6_OM/VBW3W!]:9_6N:>Q_5AA[.]!:RT
M!)B%L7%X=G5U]@'X\$5P^ONG+?I?M?3:N5U;3?.'>9H]%6\W13^.Q0>5IGJD
M511^LZR7+EILXR7.[U>7:D3>TV7BC+Q ']SC>/-HD]/7CR[O4SE1ORN)/[RT
M5\#5*YU'OS.VCB4@&^.U,3NLXHRC._ACHO-<*?OK88)Y=_CC"%!0 'X]>T 1
M5&@5[R/ NO_4U!S)L>#E:56)JP"LFC3P*UYRI#A4$)6 %*-;.<NHGO8>A'W\
M?P/T'W9(JGGN_?0S_:_F[@W)6& :7/P !=']CU7L)?:??CRXH\CTZ!6P_KN+
MP> #L/.'*7]5X8"M6HFR:&4>M'>K.GZ%4'E$;_ &57XUI&>O(@YNU (>05@$
M<@ ('W]U:?<;"7@W. 4$=U*^_3$#UNW-;0&KA@6'P96-IC\>;(H%A3,WJ*H2
MB4*-1F A*70J0R)Z2H0R5WZBI*$P<VJHF&U;?1%Q>W,'&75<5K=PNC##*QND
M<[G4LLWP Q;0,D6\&E^\95<6]2A,I#I;MP-W>'4VC&OA4;^L=LP\5C<F]X5B
MQ*? MV<YW#(30Y7?*E4M/_,R]_V]>BK"W$GI-A@K3Y-H)>+817$<&<-"4F#N
M]S-19&T&;&\1E2^6(/+G^Q*Y+I]X^CR83*-D1E*=4U$EVYJQV*J;9:D,9#1,
M716EC?)RA6A7*UYWEFBOVPE)3_K35$>,379>4GUHBS*8X# G$O5A?H/ (M/\
M?;@W]+GW+DE"<:%D5J^4BVR,Z9FZ?\)5U>UXYJ9- (\_K\"?%P0_GV']E[Y9
M-GL!6"UZF-.6IE^AB&0J\E1BS@J,ZPSMAY@68!$RQ6DRRE&W#B[>)3+J81)/
M3I("U>H_A8S*?H@T"8N +,:Z?L+*@M?W?SD#W&(1WUCG:B.;RD#MQ<EM*BD9
MK]-\MG$D9_M/\=X#\>G7_GF/E'%=NT.!I%* J=:@Y G0)N)B,E0$R9,BI^P?
M3LW4K<(B)9$6:/V^DA*L%.HD)(4/%9HTLATFVVJ6SN.K0[B$.G0[*+)VI4#!
MDZSE=!H!BAM&2ER!YPS&IJFG70>N84#'\<0P!]0 Y+!]G&H;X^0V+HLIMFND
M*F8LM/W?AV'*9YA;S3DG"<^UJ:P 8.: (#(1B0M#$&B0LBI6/?/C2(^ /^O/
MJ>FJVUF^[2H?<]_5$Q@T!DR49C*=69VO7OGX&C>:ST!3[^IVJH+77&[62FMW
MV)O'G^:U/\U:26^I*6;\S :7%&],,7 ><KM$[)O$QK]N;H,'>_Q9C_U9LZTL
MU79Y:SF7)S=)5  LN%48=F,'F3'FUAE-_:X,?#(K$+0D<".!4(",D:D!I5@]
M<KR86:&W&GZ+&\ULO+Q78'*TSU2'XE8V29H+%J6I+8Z]JI[@\N=&0?4E&,OX
MFHH\,:T1,,837CO9#-#YQ'_:>$%\KR+TGTP!\:'E-Z2L-'!>6>1\/K@X/CL2
M9[^(P;\&%V^/+_N'QR?'5[^M)KNRP[$TY@\Q +-VT;0KR:&.=#YKA(@,7@%Y
MA_I&AQ;;YV. IV)]UX(F=LB96&=/W^VXZFC<=:,Y<PGW3>C,ZS2M&;$=TP[A
M7=SMN4%_U7G!X4B0@'E0=M;P%ES-$)ABNHA>07.P&(-JI)AZS48RL%$UM6FX
MZ+/;<=#-POZ--KA9/3JWKX.X-0+#E-QF9:3XIT_'?G/X.W!%S:K.LIXUC'M3
MDGI$PKP=@ZWC ("*_RS8IE^H!&ZPO.F_X.NMR(1_HO"'JOI@EY4*#;PIM6;!
M !Q*\0UF$1DRDK9.D%1-I";D*4M5/,?N!FP&H&7B1O%@!)+B>FRB'N[2!X:T
MO&U4  11J0WAO"X$^VX;\DBC[E-LJ\#6!LQ%(7S%%##-*1_+_)XL(%_DQ0Z8
M,!QB7H+EC5GB=>EO$'!?VLCP'=TM\%Y+RP7K&,,(D]*6&83$&:H1\^@NO<LX
ME> 3SS:[[5V@.F#2XFO$0(!9B G\2O( *64L@(<SC*PGTQP;7*;&(I<_XC^I
M281"=T=S5I)VL3+<MHF3%L_!9M]=S'-M*RYD-V',JR!K60,H;M9YCKQ2<BH+
M@R=+Z\YCTRI<4C.%0<&RM.[6:05\_HC$(NZ^D]9'Q]C!$\Q8QXE)6&,^T@$9
M!E8@S,"8 Z/T!0AC HX6S1ASN<HL&1R=M75!>UBIV_$:,Q<LPN^%):G<\):C
M!(U5:4JU,WP$JG#&99(,G 7&2]=V0I271[DVDN!4DI.B,:Y(@J!(LV[')-KN
MLKJQAQF;.CC'Q;E:2!4A6X"OT],C5\R=>5-^.FP)L7<!8_00*-I*HY)II.%%
MI=U>E (K'1<"TF['KDY:?PC(D66AX[]*LUV5N2A#/F\2-2B*+MV^@UPLNLAJ
M=&PJS.Q+,1.W-$ZJ:FUW\'0*(BZH9,?=QV!V:FB_)X8%$X;<G&$X6A*XT!1E
MRU+!7K-G5146B?)KB!J'RHJ)XK@$WI,7.?,']5K'!:L".=J62=J;3$NM ORK
MT4; GQ2DH!2[G7K$L7ARBR(D"(:2=.%TD)7?,*6Z[2OYK"'0##4PF["%:;%M
M'V,%);H=+M%=5:!SDWHR'AW02'0LW#9<UD);L+E#*+D*HPQ^>8 \35*@*2DR
M2M^$K&FM8)\;OSE&!@?E5+!X%X$F0,K[",J4EQ?X3V!F8S2!*E"<E 8AWZH(
M3,_Z]HY_$T>OQGJ7BU!V.RV+Q+%%F35&,*:_V.]K=1C_M[.1NIGA-9@1_!H;
M5]K>YO)PK%J;06.43DO?73 5^<M:<]/0$L'S\"_.6RR8\3IUCYLN;NJDHZG!
M'6%2#/.R[Z7428X<Y@VW2#^ZG7+YM_CV7INDJ?'GWM)>-%]RF^S]VXTNO85P
M!C4HD'*VL'GA0I"C7*4F()Y#!Z4,D!9<7(H? #\ <QO!@JOV?1M3C8Q@RPI!
MY\<XPE QP4=O<8MALT[HA8",+FQ=H-G&T0)7JH1?.X"RUL-LE8"YD2(MD<>/
MDW@C53<)!]1/;#*?V'RM8I5*E$\$]H<W9T123S)V.T.$DKFF<)DB+U"$*I R
M#&NKGKN9>EH]D9[HG R6W0.?<W/*"B**X9-&#\SR=C\QR0(9-[9XM8)0R1H7
M;Q2Q<=3EJD-M['8\XX.Q8@'3E+E)4H ^!+CTHLB$-Y6^6I=#G3N HFV2!M@Z
M0A6LD/+2>FL"&DP'3N>D QO2$"[[7]6VDSQ:UK^_L6-I_RM!^P A][RLUD1^
M!E-J=S\M3F?YP".268[]1F56H1E"HJZ"4;$9.3<P\GW2\DG_TIOCZ\7"MV-#
M?4LDAH[ 1]IH$-(*62\W>K=#SN<[K?959"*>4:==4?4\ME6T@*6 0L!".O&4
MK0]1&1-YFCD5HJR6P*G PYP<3P$.*G+'5;@C6V5>-<W&[A4_74$0"D'WI,K-
MW"L)C)X+ZE0O-Y0[&V1KU4',@K%B6EZP/\8E8P ,M0'.DE@Q..I5 (@9))*X
MYZ13C6S*-0N!4<*H;&\5D=D5$89&II()!Q0M+<*O5X(A!J5_;98;4#Z5U^6:
M"@4[M;S5//S4,U#4585VY(L-F1S$VG!K:2P#P0KCVN71C\XH="FC7.HL1LL_
MY\6ADG@04"J.2KNP F$%7R&L-@G@8EK?-OR?*9F:=MC[,!]#T3*#<'_>$>9_
M_$[$KV!?<T9S0[-2I5;;KK*R?A73I3+ CA6S(V@5FSYV-[=AWA^Q\0^U<N $
MZ_9L'79$7(-MT]E(CQ07I),X\@X](#6QOLIQUP 1*!2?MP!ZQJ=5#K\=3<#P
M/1^3<9=Z Q?T?*<YG'EU5?ON(Y.D@SL.(48>P<]8.&DQWW?M3_I>LJ)"$%%.
MI]"X\NDOQ;$D-<E/.L;!7*54%L:K ,\2A*3..#V[&:#D'B6K\$;%9Q]0$WH/
M3T](TM I/ '/ A466&/3[K:2G(1+@EHH.H3;9@Z$>+&MU$K3A+EE<X*#D$@'
M/6FCI2%ZP0Q3S6\5DN/\M_PB?@5,#\0@IUAPJ]B)<C7V=W-1_P'V<)*O28Q6
M8/D' 2?EZH9@&4R[" H,O%C>MGY'4D=XN@G<8Q8-"19#1#FS1XFPKF#0@Q&2
MZ70A[3!;DVXK)HD<F&9/RH!G(1:*.>=2-<D8\<M65*,B<[N38\:H-N%@L[9.
MZF\FA\U'=IB8UO(-S_O !!"7D2MGJ+.L,$&*/=;#6KU5(%;O?)G@<YS<0IQY
M;?._[J^ \XH(A,7Q4:1I$J@/6$S'"!3_QL5$Z2WY!6=]RS9QOE!Z\/2U3$/$
MG-V.$:\IM;G<--*X+(80Z9+9S>5GRI?YU7RR'2 75TZ5;F:VL$""6$37)O!)
MESU EHJX2<:$R&"!8R83!"&M?2() YU(!$_3*@FM#]OU*3$>KA,]ASIYRZ/T
MRDPRM:(9%UHWYMQO L2BBL:8Q8]4U=O@[]JTFP?+N6G<2Y/0"@]HGSLG)U*K
MN7'B<)963YX6 9U=Y! !UU,P\US649CR10_:ZE^1!:A6!&M_Y+3C[E]IQX>'
MXI]6A<3/\-0<<7YQ]NGX$F#XY4IP^#.#P_OAOXN,+(?9P[K8?OO-!4X529;C
M ()+PJJAD\R $Y*A'4(CAI4ZK(QD3;P[=P_R"A)FSQ@#<PXHJZ!OS/O&N<^#
M3]"N_*]_>EHU%X,\K86<%!EEUQ#?ICKG;BJPB&$(QC2KBE_V?AUW.P':2^?H
MD*K5&$M#B!$P@LC;?@?T&Z-@ 8J,1LXI7^5SI=W$4A*72G.!>='(TH2/C&20
M@=6-;&_;M_'#B]Y:^='M> QQ'U@W9?$:JJ#0(E0!5AO#LMMGRA$G1B)YQ&.U
MA(I/1#O.I.0[K@9$_9JV$!FR>G>SR 8D=8$01;&*Q CN!?=Y"*(SG.QVF(GU
MMBE; .S9#@Z,AF84B80VG,0]0'I$>_'SDBP$4CQTYDF)QH4YTSB>+&N]:&$!
M*(V?H:YX %4%%12P/P0NASV^GIG$,'&E=LWT>L-HQ+)UT+LBC7F$:=[M&.BK
MPB>T$D(U3;*R,@'0.<NQTQE@T51J,A:2+CH*/:32BG<5D!+N6(Z02SI&RU-5
M)C_&-/PE8"S@RSF^(*I2E]S]#R#CAG:^#TD\9LL43SRYCNE$$X@4B<O96$^G
MO$^OQ)F4^3=3Y(IXJ1\ TX#>; (8'FTC +213B=.<>!Q70('C;@\C*7C?Q-&
M*TVT.>]AQ UDH Z:.RIB6VU*N<,# 1PPDG;R2CP8E?.ZW8Y_?*%I1&.L5P9&
MKIE8!2>>\6ZJ& MLYI1)6'@%6B6X]43>+NTM[1&+M;;>EN,NS!'V.1^" &\,
M^/WUIA'0I(PZIVE18'#4KTJ52!KOJ_*?JM\R19><]^J+W![!@#7)\CT^*;61
M5N*3J8AU601(89)R::^?H?G+FL?'H&V4]".%5:!?6(:C]$-6.JFZ7\+PGS-.
M$PQ2IQB:TA@*\T%6>-V.VXV"I=?8)".0]4-*ZI5EK\RGEX?+:LY\LWY,-IB5
M/-6!.>DS%F0P1MB(5#_0QCG,LT85GN[*1XS:8T'#A93BR:LPRPA"S)SFB_^*
MT#Q7$>F-HL[415.BTR) =&@Q\F05R_@%ZLD)M@69<-U1WJJ;ED[KP@.[Z#_V
M"'L(*<D_9W/[WDV?3GE$K'=(35+7JC:D,J^S=_N%'6M@=^OV U.P*PV*?RSO
M/-Q<*TZ[D!V#])";&,#K116;NAU/N>C&BG& FB93ZEE,BS+MM 3Y8EWCZ;8E
M]\C6V/5VY[D:%X7=";;]8KBQ6[:8E9V=B!UT2I//JMY')MLZ%NHA].D'6^$:
M2EC1<RSEG(6UO.'D'LMY?%S%\GA)O0"4FG<L665!VU6MS7751*OX)#R6%R__
M)^SEJ?M<."6!ZH"AFM7 MV0%8F05VHJ\<R"T.9U9^VDQ8X?LF'7K6C^<B%PH
MVK4RWV<27+1& (AAU8B+ :N0SRN43\7D2X7''8#JL(2\_D)>!O&L:8V:!SO[
M?DNC@8[ (41DY;G(<B,C;?:O5 .6-L320:7I7FEJS B(EZI!Z*]1VTBFM\2
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MP4L,5,19 ]7M.,5E3+%A,C;'C%\IKK9S'Y$<E],UJ+42M36'XA24<0):G.R
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MBZO>OOMCH?)5-16]%H  ).GRT/YQXE[\:N=GL(I;@Y/\F\]V+CS;C,3LQO(
M+]^XZ_"_R\*KW!RF\EIM#&,EO\)B,MI7^_(F B_\P#E4B /)L#7/E\@^V^R<
MPLI$K,B<X.KWT9@?9(QJ_45^-3+(YU6>4X&X FT?>OWW'P;OUMZ4&95?%B _
M4 9XU6Z19]^37[PB3F"A/ V[?E/#.)7QC&_;>=TAM_#'XUOO3L6>-F#G8K0E
M4Q6+JS&8GJ?AXA^/7\0<(Z[*WH1=PM/P[-7N=F=[>_N/Q[K?="@#T;N;:O!G
MZ$&?;;6^PM6Z]P=<K9^520"X @)SF.5I^#?(=%C<ZB 0-_ >,90&4$?$H!@
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M,@:8*M;W''9BKVS$.KO[=JNHCM9GU]I(E_#A!-)*/;$5,[9KNS=*%_<ZQ0Q
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M8RX+Q0=#V*N4S<*(%1!:A*BT,$['-?EGW*-T%=ZH^#0%:BWOX'D,4>P7:E#
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M9OU6QZ$S#^.TV7NBM$55L#XU@5O(FK71NV61[&_KZ[IH-+#5QF^=.'PH(M/
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MJU"&N5[AH&9-9HVT;(PBB*6_Z37(Z+,EL21_U'2<2Q#U^:JX408+.HAK&G)
MP/M3'?>'+*^3GUE-_34KUC07M 29EXDR.T-;$C?>3_A*F&Z'#F"W]$DS;U#F
M^Q,7"=(C2>+"\!\KN03L%=VX!Z!O>5$3>3IQIRU9R:34^/<ND_[]QQ!1X]A)
MF-W0B8C4\ +_"K>+%*.!300QO[LSK983<7CHJ]OK*A'?:?^EX;*BO*30D]-;
MWG&";I(O?Q;O)!7Y5 _\#1[X" O=W>';!5)T0MX"<V-].&_#Q=7?=*B+_-Q
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M.I?801C0@#&(@;16(OWRELO=FQ$\"M8IBN/)6,PJISAE! $Q8)HW52GQIYF
M<'1U,UW8=@[J41>:^5B]A<!>O*HJ)6*,_^1%1,"@)O6_XV;LVOC6Z]CE%G@'
MJ3ILYC&)R.VFQXN9_-UJAYG_2U]A2NQ][V><8[W"N-0LPL^6G@!.X8OI=&E!
M'&G"QR6J@T"8)E<U'=*FDTLN3"H\+'VTXK YA+)!Y3$<S/!8H,A:8!=FU4IH
M?TK[1Q4!DM/IG0[H>2QRLJ6$[F5*['.4&#R=2A<1Q#I >!YV8&'5K  Y1R5*
MP$F!"1GP)6U5+4/7 = @3#EK8J13BI3Q<PWH#@,[N/=H/W1]8 _MDCNFHAC
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MC((DZ8"PR9P8*/G'84FEN=F@G7>P&P8JVS\X$28;;/_NJS6)?W':F+[5MWA
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MMJ8Q<C31&OVCH"FQJ%%K?,ID*;](&*C-3'I_[ 795#"G?25Q@;6-,'<,>X[
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M@TVI_@]?U^%_0INJ+]&)_<UF)S:L[?6+?\&'/UW\_/+9_P-02P,$%     @
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M&V6V/LOM37_FFZMFY]#G'U!+ P04    "  QB5)40Z8X_HH&  "J1@  %0
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M7]='[#_[+">V_ -02P$"% ,4    "  QB5)4='ZW!;<8  #@E0  #@
M        @ $     9#,P.3 W.&0X:RYH=&U02P$"% ,4    "  QB5)4^&-4
M0A0-  !5-   $0              @ 'C&   9#,P.3 W.&1E>#$P,2YH=&U0
M2P$"% ,4    "  QB5)48WU;VN1/  #?A $ $0              @ $F)@
M9#,P.3 W.&1E>#$P,BYH=&U02P$"% ,4    "  QB5)4@R8;AMT=   YF
M$0              @ $Y=@  9#,P.3 W.&1E>#$P,RYH=&U02P$"% ,4
M"  QB5)4.?LT$D0;  !%C@  $0              @ %%E   9#,P.3 W.&1E
M>#$P-"YH=&U02P$"% ,4    "  QB5)4GO$I2UQ-  !Q6P$ $0
M    @ &XKP  9#,P.3 W.&1E>#$P-2YH=&U02P$"% ,4    "  QB5)48F1.
M6T(#  !?"P  $0              @ %#_0  ;'ER82TR,#(R,#(Q-BYX<V10
M2P$"% ,4    "  QB5)40Z8X_HH&  "J1@  %0              @ &T  $
M;'ER82TR,#(R,#(Q-E]L86(N>&UL4$L! A0#%     @ ,8E25$X6=*K2!
M12P  !4              ( !<0<! &QY<F$M,C R,C R,39?<')E+GAM;%!+
4!08     "0 ) #P"  !V# $    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
